UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_________________________
FORM 10-Q
x
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2015
or
¨
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from            to            
Commission File Number: 001-35568 (Healthcare Trust of America, Inc.)
Commission File Number: 333-190916 (Healthcare Trust of America Holdings, LP)
_________________________ 
HEALTHCARE TRUST OF AMERICA, INC.
HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
(Exact name of registrant as specified in its charter)
Maryland (Healthcare Trust of America, Inc.)
 
20-4738467
Delaware (Healthcare Trust of America Holdings, LP)
 
20-4738347
(State or other jurisdiction of
incorporation or organization)
 
(I.R.S. Employer
Identification No.)
16435 N. Scottsdale Road, Suite 320
Scottsdale, Arizona 85254
(Address of principal executive offices)
(480) 998-3478
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Sections 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    
Healthcare Trust of America, Inc.
x Yes
¨ No
 
Healthcare Trust of America Holdings, LP
x Yes
¨ No
 
Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    
Healthcare Trust of America, Inc.
x Yes
¨ No
 
Healthcare Trust of America Holdings, LP
x Yes
¨ No
 
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.
Healthcare Trust of America, Inc.
Large-accelerated filer x
Accelerated filer ¨
Non-accelerated filer ¨
Smaller reporting company ¨
 
 
 
(Do not check if a smaller reporting company)
 
Healthcare Trust of America Holdings, LP
Large-accelerated filer ¨
Accelerated filer ¨
Non-accelerated filer x
Smaller reporting company ¨
 
 
 
(Do not check if a smaller reporting company)
 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     
Healthcare Trust of America, Inc.
¨ Yes
x No
 
Healthcare Trust of America Holdings, LP
¨ Yes
x No
 

As of July 27, 2015 , there were 127,040,154 shares of Class A common stock of Healthcare Trust of America, Inc. outstanding.
 


Explanatory Note
This Quarterly Report combines the Quarterly Reports on Form 10-Q for the quarter ended June 30, 2015 of Healthcare Trust of America, Inc. (“HTA”), a Maryland corporation, and Healthcare Trust of America Holdings, LP (“ HTALP ”), a Delaware limited partnership. Unless otherwise indicated or unless the context requires otherwise, all references in this Quarterly Report to “we,” “us,” “our,” “the Company” or “our Company” refer to HTA and HTALP , collectively, and all references to “common stock” shall refer to the Class A common stock of HTA.
HTA operates as a real estate investment trust (“REIT”) and is the general partner of HTALP . As of June 30, 2015 , HTA owned a 98.5% partnership interest in HTALP , and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the long-term incentive plan (“LTIP”) units) in HTALP . As the sole general partner of HTALP , HTA has the full, exclusive and complete responsibility for HTALP ’s day-to-day management and control, including its compliance with the Securities and Exchange Commission (“SEC”) filing requirements.
We believe it is important to understand the few differences between HTA and HTALP in the context of how we operate as an integrated consolidated company. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP . As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP , issuing public equity from time to time and guaranteeing certain debts of HTALP . HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity. Except for net proceeds from public equity issuances by HTA, which are generally contributed to HTALP in exchange for partnership units of HTALP , HTALP generates the capital required for the business through its operations and by direct or indirect incurrence of indebtedness or through the issuance of its partnership units.
Stockholders’ equity and partners’ capital are the primary areas of difference between the condensed consolidated financial statements of HTA and HTALP . Limited partnership units in HTALP are accounted for as partners’ capital in HTALP ’s condensed consolidated balance sheets and as noncontrolling interest reflected within equity in HTA’s condensed consolidated balance sheets. The differences between HTA’s stockholders’ equity and HTALP ’s partners’ capital are due to the differences in the equity issued by HTA and HTALP , respectively.
The Company believes combining the Quarterly Reports on Form 10-Q of HTA and HTALP , including the notes to the condensed consolidated financial statements, into this single Quarterly Report results in the following benefits:
•
enhances stockholders’ understanding of HTA and HTALP by enabling stockholders to view the business as a whole in the same manner that management views and operates the business;
•
eliminates duplicative disclosure and provides a more streamlined and readable presentation since a substantial portion of the disclosure in this Quarterly Report applies to both HTA and HTALP ; and
•
creates time and cost efficiencies through the preparation of a single Quarterly Report instead of two separate Quarterly Reports.
In order to highlight the material differences between HTA and HTALP , this Quarterly Report includes sections that separately present and discuss areas that are materially different between HTA and HTALP , including:
•
the condensed consolidated financial statements;
•
certain accompanying notes to the condensed consolidated financial statements, including Note 7 - Debt, Note 9 - Stockholders’ Equity and Partners’ Capital, Note 11 - Per Share Data of HTA and Note 12 - Per Unit Data of HTALP ;
•
the Funds From Operations (“FFO”) and Normalized FFO in Part I, Item 2 of this Quarterly Report;
•
the controls and procedures in Part I, Item 4 of this Quarterly Report; and
•
the certifications of the Chief Executive Officer and the Chief Financial Officer included as Exhibits 31 and 32 to this Quarterly Report.
In the sections of this Quarterly Report that combine disclosure for HTA and HTALP , this Quarterly Report refers to actions or holdings as being actions or holdings of the Company. Although HTALP (directly or indirectly through one of its subsidiaries) is generally the entity that enters into contracts, holds assets and issues or incurs debt, management believes this presentation is appropriate for the reasons set forth above and because the business of the Company is a single integrated enterprise operated through HTALP .

2


HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
TABLE OF CONTENTS
 
 
 
Page
Healthcare Trust of America, Inc.
 
 
 
 
 
Healthcare Trust of America Holdings, LP
 
 
 
 
 
Notes for Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP
 
 
 
 
 
 
 
 
 




3

Table of Contents

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements (Unaudited)

HEALTHCARE TRUST OF AMERICA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share data)
(Unaudited)
 
 
June 30, 2015
 
December 31, 2014
ASSETS
 
 
 
 
Real estate investments:
 
 
 
 
Land
 
$
298,995

 
$
287,755

Building and improvements
 
2,872,709

 
2,665,777

Lease intangibles
 
435,218

 
419,288

 
 
3,606,922

 
3,372,820

Accumulated depreciation and amortization
 
(617,105
)
 
(549,976
)
Real estate investments, net ($0 and $80,419 from consolidated VIEs, see Note 2)
 
2,989,817

 
2,822,844

Cash and cash equivalents
 
16,577

 
10,413

Restricted cash and escrow deposits
 
16,249

 
20,799

Receivables and other assets, net
 
148,343

 
144,106

Other intangibles, net
 
47,126

 
43,488

Total assets
 
$
3,218,112

 
$
3,041,650

LIABILITIES AND EQUITY
 
 
 
 
Liabilities:
 
 
 
 
Debt
 
$
1,639,001

 
$
1,412,461

Accounts payable and accrued liabilities
 
85,003

 
101,042

Derivative financial instruments - interest rate swaps
 
2,721

 
2,888

Security deposits, prepaid rent and other liabilities
 
43,176

 
32,687

Intangible liabilities, net
 
23,585

 
12,425

Total liabilities
 
1,793,486

 
1,561,503

Commitments and contingencies
 

 

Redeemable noncontrolling interests
 
3,744

 
3,726

Equity:
 
 
 
 
Preferred stock, $0.01 par value; 200,000,000 shares authorized; none issued and outstanding
 
—

 
—

Class A common stock, $0.01 par value; 1,000,000,000 shares authorized; 125,194,108 and 125,087,268 shares issued and outstanding as of June 30, 2015 and December 31, 2014, respectively
 
1,252

 
1,251

Additional paid-in capital
 
2,283,737

 
2,281,932

Cumulative dividends in excess of earnings
 
(892,543
)
 
(836,044
)
Total stockholders’ equity
 
1,392,446

 
1,447,139

Noncontrolling interests
 
28,436

 
29,282

Total equity
 
1,420,882

 
1,476,421

Total liabilities and equity
 
$
3,218,112

 
$
3,041,650

 
 
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.

4

Table of Contents

HEALTHCARE TRUST OF AMERICA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share data)
(Unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Revenues:
 
 
 
 
 
 
 
Rental income
$
99,243

 
$
88,946

 
$
197,695

 
$
179,398

Interest and other operating income
68

 
725

 
136

 
1,577

Total revenues
99,311

 
89,671

 
197,831

 
180,975

Expenses:
 
 
 
 
 
 
 
Rental
29,237

 
27,064

 
59,934

 
56,653

General and administrative
6,224

 
5,903

 
12,799

 
12,202

Acquisition-related  
1,101

 
4,869

 
2,458

 
5,845

Depreciation and amortization
38,066

 
33,602

 
74,661

 
68,544

Impairment
1,655

 
—

 
1,655

 
—

Total expenses
76,283

 
71,438

 
151,507

 
143,244

Income before other income (expense)
23,028

 
18,233

 
46,324

 
37,731

Interest expense:
 
 
 
 
 
 
 
Interest related to derivative financial instruments
(820
)
 
(1,370
)
 
(1,375
)
 
(2,715
)
Net gain (loss) on change in fair value of derivative financial instruments
1,314

 
(2,580
)
 
(696
)
 
(3,421
)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments
494

 
(3,950
)
 
(2,071
)
 
(6,136
)
Interest related to debt
(14,159
)
 
(11,779
)
 
(27,963
)
 
(23,683
)
Gain on extinguishment of debt
121

 
365

 
121

 
365

Other income
4

 
14

 
19

 
40

Net income
$
9,488

 
$
2,883

 
$
16,430

 
$
8,317

Net income attributable to noncontrolling interests (1)  
(196
)
 
(28
)
 
(334
)
 
(170
)
Net income attributable to common stockholders
$
9,292

 
$
2,855

 
$
16,096

 
$
8,147

Earnings per common share - basic: (2)  
 
 
 
 
 
 
 
Net income attributable to common stockholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Earnings per common share - diluted: (2)  
 
 
 
 
 
 
 
Net income attributable to common stockholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Weighted average number of common shares outstanding: (2)
 
 
 
 
 
 
 
Basic
125,194

 
119,012

 
125,184

 
118,829

Diluted
127,124

 
120,275

 
127,114

 
120,094

Dividends declared per common share (2)
$
0.29

 
$
0.29

 
$
0.58

 
$
0.58

 
 
 
 
 
 
 
 
(1) Includes amounts attributable to redeemable noncontrolling interests.
(2) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
The accompanying notes are an integral part of these condensed consolidated financial statements.

5


HEALTHCARE TRUST OF AMERICA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(In thousands)
(Unaudited)
 
Class A Common Stock (1)
 
Additional Paid-In Capital (1)
 
Cumulative Dividends in Excess of Earnings
 
Total Stockholders’ Equity
 
Noncontrolling Interest
 
Total Equity
 
Shares
 
Amount
Balance as of December 31, 2013
118,440

 
$
1,184

 
$
2,128,082

 
$
(742,060
)
 
$
1,387,206

 
$
12,543

 
$
1,399,749

Issuance of common stock
771

 
8

 
17,734

 
—

 
17,742

 
—

 
17,742

Share-based award transactions, net
248

 
3

 
2,251

 
—

 
2,254

 
—

 
2,254

Repurchase and cancellation of common stock
(29
)
 
(1
)
 
(571
)
 
—

 
(572
)
 
—

 
(572
)
Redemption of noncontrolling interest
25

 
—

 
244

 
—

 
244

 
(244
)
 
—

Dividends
—

 
—

 
—

 
(68,453
)
 
(68,453
)
 
(693
)
 
(69,146
)
Net income
—

 
—

 
—

 
8,147

 
8,147

 
87

 
8,234

Balance as of June 30, 2014
119,455

 
$
1,194

 
$
2,147,740

 
$
(802,366
)
 
$
1,346,568

 
$
11,693

 
$
1,358,261

 
 
 
 
 
 
 
 
 
 
 
 
 
 
Balance as of December 31, 2014
125,087

 
$
1,251

 
$
2,281,932

 
$
(836,044
)
 
$
1,447,139

 
$
29,282

 
$
1,476,421

Share-based award transactions, net
155

 
1

 
3,103

 
—

 
3,104

 
—

 
3,104

Repurchase and cancellation of common stock
(48
)
 
—

 
(1,298
)
 
—

 
(1,298
)
 
—

 
(1,298
)
Dividends
—

 
—

 
—

 
(72,595
)
 
(72,595
)
 
(1,123
)
 
(73,718
)
Net income
—

 
—

 
—

 
16,096

 
16,096

 
277

 
16,373

Balance as of June 30, 2015
125,194

 
$
1,252

 
$
2,283,737

 
$
(892,543
)
 
$
1,392,446

 
$
28,436

 
$
1,420,882

 
 
 
 
 
 
 
 
 
 
 
 
 
 
(1) For the six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
The accompanying notes are an integral part of these condensed consolidated financial statements.

6


HEALTHCARE TRUST OF AMERICA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
(Unaudited)
 
Six Months Ended June 30,
 
2015
 
2014
Cash flows from operating activities:
 
 
 
Net income
$
16,430

 
$
8,317

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation, amortization and other
72,905

 
66,990

Share-based compensation expense
3,104

 
2,254

Bad debt expense
289

 
(40
)
Impairment
1,655

 
—

Gain on extinguishment of debt
(121
)
 
(365
)
Change in fair value of derivative financial instruments
696

 
3,421

Changes in operating assets and liabilities:
 
 
 
Receivables and other assets, net
(3,885
)
 
(2,864
)
Accounts payable and accrued liabilities
(12,024
)
 
(2,136
)
Security deposits, prepaid rent and other liabilities
8,117

 
(2,365
)
Net cash provided by operating activities
87,166

 
73,212

Cash flows from investing activities:
 
 
 
Acquisition of real estate operating properties
(224,345
)
 
(123,186
)
Capital expenditures
(13,131
)
 
(10,264
)
Collection of real estate notes receivable
—

 
15,000

Restricted cash, escrow deposits and other assets
4,550

 
(1,236
)
Net cash used in investing activities
(232,926
)
 
(119,686
)
Cash flows from financing activities:
 
 
 
Proceeds from unsecured senior notes
—

 
297,615

Borrowings on unsecured revolving credit facility
361,000

 
153,000

Payments on unsecured revolving credit facility
(167,000
)
 
(208,000
)
Borrowings on unsecured term loans
100,000

 
—

Payments on secured real estate term loan and mortgage loans
(67,171
)
 
(27,214
)
Deferred financing costs
(276
)
 
(3,553
)
Security deposits
183

 
858

Proceeds from issuance of common stock, net
—

 
18,016

Repurchase and cancellation of common stock
(1,298
)
 
(572
)
Dividends
(72,584
)
 
(68,161
)
Distributions to noncontrolling interest of limited partners
(930
)
 
(877
)
Net c ash provided by fi nancing activities
151,924

 
161,112

Net change in cash and cash equivalents
6,164

 
114,638

Cash and cash equivalents - beginning of period
10,413

 
18,081

Cash and cash equivalents - end of period
$
16,577

 
$
132,719

The accompanying notes are an integral part of these condensed consolidated financial statements.

7


HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except unit data)
(Unaudited)
 
 
June 30, 2015
 
December 31, 2014
ASSETS
 
 
 
 
Real estate investments:
 
 
 
 
Land
 
$
298,995

 
$
287,755

Building and improvements
 
2,872,709

 
2,665,777

Lease intangibles
 
435,218

 
419,288

 
 
3,606,922

 
3,372,820

Accumulated depreciation and amortization
 
(617,105
)
 
(549,976
)
Real estate investments, net ($0 and $80,419 from consolidated VIEs, see Note 2)
 
2,989,817

 
2,822,844

Cash and cash equivalents
 
16,577

 
10,413

Restricted cash and escrow deposits
 
16,249

 
20,799

Receivables and other assets, net
 
148,343

 
144,106

Other intangibles, net
 
47,126

 
43,488

Total assets
 
$
3,218,112

 
$
3,041,650

LIABILITIES AND PARTNERS’ CAPITAL
 
 
 
 
Liabilities:
 
 
 
 
Debt
 
$
1,639,001

 
$
1,412,461

Accounts payable and accrued liabilities
 
85,003

 
101,042

Derivative financial instruments - interest rate swaps
 
2,721

 
2,888

Security deposits, prepaid rent and other liabilities
 
43,176

 
32,687

Intangible liabilities, net
 
23,585

 
12,425

Total liabilities
 
1,793,486

 
1,561,503

Commitments and contingencies
 


 


Redeemable noncontrolling interests
 
3,744

 
3,726

Partners’ Capital:
 
 
 
 
Limited partners’ capital, 1,929,942 and 2,154,942 units issued and outstanding as of June 30, 2015 and December 31, 2014, respectively
 
28,166

 
29,012

General partners’ capital, 125,194,108 and 125,087,268 units issued and outstanding as of June 30, 2015 and December 31, 2014, respectively
 
1,392,716

 
1,447,409

Total partners’ capital
 
1,420,882

 
1,476,421

Total liabilities and partners’ capital
 
$
3,218,112

 
$
3,041,650

 
 
 
 
 
The accompanying notes are an integral part of these condensed consolidated financial statements.


8


HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per unit data)
  (Unaudited)
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Revenues:
 
 
 
 
 
 
 
Rental income
$
99,243

 
$
88,946

 
$
197,695

 
$
179,398

Interest and other operating income
68

 
725

 
136

 
1,577

Total revenues
99,311

 
89,671

 
197,831

 
180,975

Expenses:
 
 
 
 
 
 
 
Rental
29,237

 
27,064

 
59,934

 
56,653

General and administrative
6,224

 
5,903

 
12,799

 
12,202

Acquisition-related  
1,101

 
4,869

 
2,458

 
5,845

Depreciation and amortization
38,066

 
33,602

 
74,661

 
68,544

Impairment
1,655

 
—

 
1,655

 
—

Total expenses
76,283

 
71,438

 
151,507

 
143,244

Income before other income (expense)
23,028

 
18,233

 
46,324

 
37,731

Interest expense:
 
 
 
 
 
 
 
Interest related to derivative financial instruments
(820
)
 
(1,370
)
 
(1,375
)
 
(2,715
)
Net gain (loss) on change in fair value of derivative financial instruments
1,314

 
(2,580
)
 
(696
)
 
(3,421
)
Total interest related to derivative financial instruments, including net change in fair value of derivative financial instruments
494

 
(3,950
)
 
(2,071
)
 
(6,136
)
Interest related to debt
(14,159
)
 
(11,779
)
 
(27,963
)
 
(23,683
)
Gain on extinguishment of debt
121

 
365

 
121

 
365

Other income
4

 
14

 
19

 
40

Net income
$
9,488

 
$
2,883

 
$
16,430

 
$
8,317

Net income attributable to noncontrolling interests
(24
)
 
(40
)
 
(57
)
 
(78
)
Net income attributable to common unitholders
$
9,464

 
$
2,843

 
$
16,373

 
$
8,239

Earnings per common unit - basic: (1)
 
 
 
 
 
 
 
Net income attributable to common unitholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Earnings per common unit - diluted: (1)
 
 
 
 
 
 
 
Net income attributable to common unitholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Weighted average number of common units outstanding:  (1)
 
 
 
 
 
 
 
Basic
127,203

 
120,534

 
127,266

 
120,353

Diluted
127,203

 
120,534

 
127,266

 
120,353

Distributions declared per common unit (1)
$
0.29

 
$
0.29

 
$
0.58

 
$
0.58

 
 
 
 
 
 
 
 
(1) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
The accompanying notes are an integral part of these condensed consolidated financial statements.

9


HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN PARTNERS ’ CAPITAL
(In thousands)
  (Unaudited)
 
General Partners’ Capital
 
Limited Partners’ Capital
 
Total Partners’ Capital
 
Units (1)
 
Amount
 
Units (1)
 
Amount
 
Balance as of December 31, 2013
118,440

 
$
1,387,476

 
1,527

 
$
13,818

 
$
1,401,294

Issuance of general partner units
771

 
17,742

 
—

 
—

 
17,742

Share-based award transactions, net
248

 
2,254

 
—

 
—

 
2,254

Redemptions of general partner units
(29
)
 
(572
)
 
—

 
—

 
(572
)
Redemption of limited partner units
25

 
244

 
(25
)
 
(244
)
 
—

Distributions
—

 
(68,453
)
 
—

 
(737
)
 
(69,190
)
Net income
—

 
8,147

 
—

 
92

 
8,239

Balance as of June 30, 2014
119,455

 
$
1,346,838

 
1,502

 
$
12,929

 
$
1,359,767

 
 
 
 
 
 
 
 
 
 
Balance as of December 31, 2014
125,087

 
$
1,447,409

 
2,155

 
$
29,012

 
$
1,476,421

Share-based award transactions, net
155

 
3,104

 
(225
)
 
—

 
3,104

Redemption of general partner units
(48
)
 
(1,298
)
 
—

 
—

 
(1,298
)
Distributions
—

 
(72,595
)
 
—

 
(1,123
)
 
(73,718
)
Net income
—

 
16,096

 
—

 
277

 
16,373

Balance as of June 30, 2015
125,194

 
$
1,392,716

 
1,930

 
$
28,166

 
$
1,420,882

 
 
 
 
 
 
 
 
 
 
(1) For the six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
The accompanying notes are an integral part of these condensed consolidated financial statements.


10


HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
  (Unaudited)
 
Six Months Ended June 30,
 
2015
 
2014
Cash flows from operating activities:
 
 
 
Net income
$
16,430

 
$
8,317

Adjustments to reconcile net income to net cash provided by operating activities:
 
 
 
Depreciation, amortization and other
72,905

 
66,990

Share-based compensation expense
3,104

 
2,254

Bad debt expense
289

 
(40
)
Impairment
1,655

 
—

Gain on extinguishment of debt
(121
)
 
(365
)
Change in fair value of derivative financial instruments
696

 
3,421

Changes in operating assets and liabilities:
 
 
 
Receivables and other assets, net
(3,885
)
 
(2,864
)
Accounts payable and accrued liabilities
(12,024
)
 
(2,136
)
Security deposits, prepaid rent and other liabilities
8,117

 
(2,365
)
Net cash provided by operating activities
87,166

 
73,212

Cash flows from investing activities:
 
 
 
Acquisition of real estate operating properties
(224,345
)
 
(123,186
)
Capital expenditures
(13,131
)
 
(10,264
)
Collection of real estate notes receivable
—

 
15,000

Restricted cash, escrow deposits and other assets
4,550

 
(1,236
)
Net cash used in investing activities
(232,926
)
 
(119,686
)
Cash flows from financing activities:
 
 
 
Proceeds from unsecured senior notes
—

 
297,615

Borrowings on unsecured revolving credit facility
361,000

 
153,000

Payments on unsecured revolving credit facility
(167,000
)
 
(208,000
)
Borrowings on unsecured term loans
100,000

 
—

Payments on secured real estate term loan and mortgage loans
(67,171
)
 
(27,214
)
Deferred financing costs
(276
)
 
(3,553
)
Security deposits
183

 
858

Proceeds from issuance of general partner units, net
—

 
18,016

Repurchase and cancellation of general partner units
(1,298
)
 
(572
)
Distributions to general partner
(72,584
)
 
(68,161
)
Distributions to limited partners and redeemable noncontrolling interests
(930
)
 
(877
)
N et cash provided by fi nancing activities
151,924

 
161,112

Net change in cash and cash equivalents
6,164

 
114,638

Cash and cash equivalents - beginning of period
10,413

 
18,081

Cash and cash equivalents - end of period
$
16,577

 
$
132,719

The accompanying notes are an integral part of these condensed consolidated financial statements.

11


HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unless otherwise indicated or unless the context requires otherwise the use of the words “we,” “us” or “our” refers to Healthcare Trust of America, Inc. and Healthcare Trust of America Holdings, LP, collectively.
1. Organization and Description of Business
HTA, a Maryland corporation, and HTALP , a Delaware limited partnership, were incorporated or formed, as applicable, on April 20, 2006 . HTA operates as a REIT and is the general partner of HTALP , which is the operating partnership. As of June 30, 2015 , HTA owned a 98.5% partnership interest and other limited partners, including some of HTA’s directors, executive officers and their affiliates, owned the remaining partnership interest (including the LTIP units) in HTALP . As the sole general partner of HTALP , HTA has the full, exclusive and complete responsibility for HTALP ’s day-to-day management and control. HTA operates in an umbrella partnership REIT structure in which HTALP and its subsidiaries hold substantially all of the assets. HTA’s only material asset is its ownership of partnership interests of HTALP . As a result, HTA does not conduct business itself, other than acting as the sole general partner of HTALP , issuing public equity from time to time and guaranteeing certain debts of HTALP . HTALP conducts the operations of the business and issues publicly-traded debt, but has no publicly-traded equity.
HTA is one of the largest publicly-traded REITs focused on medical office buildings (“MOBs”) in the United States (“U.S.”) based on gross leasable area (“GLA”). We are primarily focused on acquiring, owning and operating high quality MOBs that are predominantly located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. In addition, we have strong industry relationships, a stable and diversified tenant mix and an extensive and active acquisition network. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments that provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective, we: (i) seek internal growth through proactive asset management, leasing and property management oversight; (ii) target mid-sized acquisitions of MOBs in markets with dominant healthcare systems, and with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with conservative leverage. HTA has qualified to be taxed as a REIT for federal income tax purposes and intends to continue to be taxed as a REIT.
We primarily invest in MOBs that are located on health system campuses, in community-core locations, or around university medical centers which we believe are core, critical real estate. We also focus on our key markets that have certain demographic and macro-economic trends and where we can utilize our institutional property management and leasing platform to generate strong tenant relationships and operating cost efficiencies. Our portfolio consists of MOBs and other facilities that serve the healthcare industry with an aggregate purchase price of $3.6 billion through June 30, 2015 .
Effective December 15, 2014, HTA completed a reverse stock split (the “Reverse Stock Split”) of its common stock. As a result of the Reverse Stock Split, every two issued and outstanding shares of common stock were converted into one share of common stock. HTA’s par value and shares authorized remained unchanged. Concurrently with the Reverse Stock Split, HTALP effected a corresponding Reverse Stock Split of its outstanding units of limited partnership interests. The weighted average number of shares/units and per share/unit amounts for the three and six months ended June 30, 2014 have been adjusted retroactively to reflect the Reverse Stock Split.
Our principal executive office is located at 16435 North Scottsdale Road, Suite 320, Scottsdale, Arizona, 85254.
2. Summary of Significant Accounting Policies
The summary of significant accounting policies presented below is designed to assist in understanding our condensed consolidated financial statements. Such condensed consolidated financial statements and the accompanying notes are the representations of our management, who are responsible for their integrity and objectivity. These accounting policies conform to U.S. generally accepted accounting principles (“GAAP”), in all material respects, and have been consistently applied in preparing our accompanying condensed consolidated financial statements.
Basis of Presentation
Our accompanying condensed consolidated financial statements include our accounts and those of our subsidiaries and any consolidated variable interest entities (“VIEs”). All inter-company balances and transactions have been eliminated in the accompanying condensed consolidated financial statements.

12

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Interim Unaudited Financial Data
Our accompanying condensed consolidated financial statements have been prepared by us in accordance with GAAP in conjunction with the rules and regulations of the SEC. Certain information and footnote disclosures required for annual financial statements have been condensed or excluded pursuant to SEC rules and regulations. Accordingly, our accompanying condensed consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. Our accompanying condensed consolidated financial statements reflect all adjustments, which are, in our opinion, of a normal recurring nature and necessary for a fair presentation of our financial position, results of operations and cash flows for the interim periods. Interim results of operations are not necessarily indicative of the results to be expected for the full year; such results may be less favorable for the full year. Our accompanying condensed consolidated financial statements should be read in conjunction with our audited consolidated financial statements and the notes thereto included in our 2014 Annual Report on Form 10-K.
Variable Interest Entities
During 2014, we made loans totaling $80.5 million to five entities to acquire MOBs in order to facilitate potential Internal Revenue Code Section 1031 tax-deferred exchanges (the “Exchanges”). As of December 31, 2014 , our consolidated financial statements included the five VIEs as we were deemed to be the primary beneficiary. During the three months ended June 30, 2015 , we elected not to consummate the five outstanding Exchanges and accordingly the rights to the title and interests of the MOBs were transferred to us.
Real Estate Investments
Depreciation expense of buildings and improvements for the three months ended June 30, 2015 and 2014 , was $24.7 million and $21.0 million , respectively. Depreciation expense of buildings and improvements for the six months ended June 30, 2015 and 2014 , was $48.0 million and $42.4 million , respectively.
Recoverability of Real Estate Investments
Operating properties are evaluated for potential impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Impairment losses are recorded when indicators of impairment are present and the carrying amount of the asset is greater than the sum of future undiscounted cash flows expected to be generated by that asset over the remaining expected holding period. We would recognize an impairment loss when the carrying amount is not recoverable to the extent the carrying amount exceeds the fair value of the property. The fair value is generally based on discounted cash flow analyses, based on executed sales agreements or management’s best estimate of market comparables, future occupancy levels, rental rates, capitalization rates, lease-up periods and capital requirements. See Note 4 for further discussion.
Recently Issued or Adopted Accounting Pronouncements
In May 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”) 2014-09, Revenue from Contracts with Customers (Topic 606). ASU 2014-09 is a comprehensive new revenue recognition model requiring a company to recognize revenue to depict the transfer of goods or services to customers in amounts that reflect the consideration (i.e., payment) to which the company expects to be entitled in exchange for those goods or services. In adopting ASU 2014-09, companies may use either a full retrospective or a modified retrospective approach. In July 2015, the FASB deferred the effective date of ASU 2014-09 to the first interim period within annual reporting periods beginning after December 15, 2017 along with the ability to early adopt as of the original effective date. We do not anticipate early adoption and are still evaluating the impact of adopting ASU 2014-09 on our financial statements.
In February 2015, the FASB issued ASU 2015-02, Consolidation - Amendments to the Consolidation Analysis (Topic 810). ASU 2015-02 affects reporting entities that are required to evaluate whether they should consolidate certain legal entities. The amendments in ASU 2015-02 affect the following areas: (i) limited partnerships and similar legal entities; (ii) evaluating fees paid to a decision maker or a service provider as a variable interest; (iii) the effect of fee arrangements on the primary beneficiary determination; (iv) the effect of related parties on the primary beneficiary determination; and (v) certain investment funds. ASU 2015-02 is effective for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015 with early adoption permitted. We do not believe ASU 2015-02 will have a significant impact on our financial statements.

13

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

In April 2015, the FASB issued ASU 2015-03, Interest - Imputation of Interest (Subtopic 835-30). ASU 2015-03 changes the presentation of debt issuance costs by requiring these costs related to a recognized debt liability to be presented in the consolidated balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. The recognition and measurement guidance for debt issuance costs are not affected by these amendments. ASU 2015-03 is effective for the fiscal years beginning after December 15, 2015, and requires retrospective application. We are still evaluating the impact of adopting ASU 2015-03 on our financial statements.
3. Business Combinations
For the six months ended June 30, 2015 , our acquisitions had an aggregate purchase price of $225.5 million . We incurred $1.0 million of costs attributable to these acquisitions, which were recorded in acquisition-related expenses in the accompanying condensed consolidated statements of operations.
Since the acquisitions were determined to be individually not significant, but significant on a collective basis, the allocations for the 2015 acquisitions are set forth below in the aggregate (in thousands):
Acquisitions through June 30, 2015
 
Total
Land
 
$
11,240

Building and improvements
 
200,071

Below market leasehold interests
 
2,350

Above market leases
 
3,279

In place leases
 
19,403

Below market leases
 
(5,912
)
Above market leasehold interests
 
(6,086
)
Net assets acquired
 
224,345

Other, net
 
1,165

Aggregate purchase price
 
$
225,510

The acquired intangible assets and liabilitie s, referenced above, had weighted average lives of 15.5 years and 47.0 years , respectively.
The acquisitions completed during the six months ended June 30, 2014 were determined to be individually not significant, but significant on a collective basis. The allocations for these acquisitions are set forth below in the aggregate (in thousands):
Acquisitions through June 30, 2014
 
Total
Land
 
$
46,102

Building and improvements
 
153,186

Below market leasehold interests
 
98

Above market leases
 
871

In place leases
 
15,112

Below market leases
 
(674
)
Above market debt, net
 
(2,664
)
Net assets acquired
 
212,031

Other, net
 
(531
)
Aggregate purchase price
 
$
211,500

The acquired intangible assets and liabilities, referenced above, had weighted average lives of 11.1 years and 9.4 years , respectively.
4. Impairment and Dispositions
During the six months ended June 30, 2015 , we recorded an impairment charge of $1.7 million on a MOB that was being marketed for sale. In July 2015, we completed the disposition of this building and a separate portfolio of MOBs for an aggregate gross sales price of $34.9 million . These dispositions did not meet the requirements to be classified as held for sale as of June 30, 2015, as due diligence was on-going and the completion of the sales were not reasonably assured as of the end of the quarter.

14

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

5. Intangible Assets and Liabilities
Intangible assets and liabilities consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands, except weighted average remaining amortization period):
 
June 30, 2015
 
December 31, 2014
 
 
 
Balance
 
Weighted Average Remaining Amortization Period in Years
 
Balance
 
Weighted Average Remaining Amortization Period in Years
 
Balance Sheet Classification
Assets:
 
 
 
 
 
 
 
 
 
In place leases
$
249,330

 
9.2
 
$
231,370

 
8.8
 
Lease intangibles
Tenant relationships
185,888

 
10.4
 
187,918

 
10.3
 
Lease intangibles
Above market leases
29,944

 
5.8
 
26,676

 
5.5
 
Other intangibles, net
Below market leasehold interests
35,300

 
64.1
 
32,950

 
67.3
 
Other intangibles, net
 
500,462

 
 
 
478,914

 
 
 
 
Accumulated amortization
(204,760
)
 
 
 
(182,149
)
 
 
 
 
Total
$
295,702

 
15.4
 
$
296,765

 
15.2
 
 
 
 
 
 
 
 
 
 
 
 
Liabilities:
 
 
 
 
 
 
 
 
 
Below market leases
$
20,043

 
19.1
 
$
14,188

 
11.5
 
Intangible liabilities, net
Above market leasehold interests
9,943

 
52.5
 
3,857

 
32.1
 
Intangible liabilities, net
 
29,986

 
 
 
18,045

 
 
 
 
Accumulated amortization
(6,401
)
 
 
 
(5,620
)
 
 
 
 
Total
$
23,585

 
32.4
 
$
12,425

 
17.1
 
 
The following is a summary of the net intangible amortization for the three and six months ended June 30, 2015 and 2014 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Amortization recorded against rental income related to above or below market leases
$
444

 
$
509

 
$
919

 
$
1,029

Rental expense related to above or below market leasehold interests
128

 
98

 
233

 
246

Amortization expense related to in place leases and tenant relationships
12,149

 
11,699

 
24,105

 
24,181

6. Receivables and Other Assets
Receivables and other assets consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):
 
June 30, 2015
 
December 31, 2014
Accounts receivables, net
$
20,631

 
$
16,468

Other receivables
8,313

 
10,639

Deferred financing costs, net
15,528

 
16,929

Deferred leasing costs, net
18,086

 
17,281

Straight-line rent receivables, net
61,731

 
56,433

Prepaid expenses, deposits, equipment and other, net
23,203

 
24,642

Derivative financial instruments - interest rate swaps
851

 
1,714

Total
$
148,343

 
$
144,106


15

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following is a summary of amortization of deferred leasing costs and deferred financing costs for the three and six months ended June 30, 2015 and 2014 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Amortization expense related to deferred leasing costs
$
942

 
$
815

 
$
1,928

 
$
1,689

Interest expense related to deferred financing costs
841

 
629

 
1,683

 
1,595

7. Debt
Debt consisted of the following as of June 30, 2015 and December 31, 2014 (in thousands):
 
 
June 30, 2015
 
December 31, 2014
Unsecured revolving credit facility
 
$
230,000

 
$
36,000

Unsecured term loans
 
455,000

 
355,000

Unsecured senior notes
 
600,000

 
600,000

Fixed rate mortgages
 
325,464

 
392,399

Variable rate mortgages
 
29,238

 
29,474

 
 
1,639,702

 
1,412,873

Net discount
 
(701
)
 
(412
)
Total
 
$
1,639,001

 
$
1,412,461

Unsecured Credit Agreement
Unsecured Revolving Credit Facility
On February 11, 2015 , HTA and HTALP executed an amendment to the unsecured revolving credit and term loan facility (the “Unsecured Credit Agreement”) which added an additional lender and increased the amount available under the unsecured revolving credit facility from $800.0 million to $850.0 million . The other existing terms of the Unsecured Credit Agreement were unchanged. The actual amount of credit available to us is a function of certain loan-to-value and debt service coverage ratios set forth in the credit facility. The maximum principal amount of the credit facility may be increased, subject to additional financing being provided by our existing lenders or new lenders being added to the unsecured revolving credit facility. The unsecured revolving credit facility matures on January 31, 2020 .
Borrowings under the unsecured revolving credit facility accrue interest equal to adjusted LIBOR , plus a margin ranging from 0.875% to 1.55% per annum based on our credit rating. We also pay a facility fee ranging from 0.125% to 0.30% per annum on the aggregate commitments under the unsecured revolving credit facility. As of June 30, 2015 , the margin associated with our borrowings was 1.05% per annum and the facility fee was 0.20% per annum.
Unsecured Term Loan
As of June 30, 2015 , we had a $300.0 million unsecured term loan outstanding that was guaranteed by HTA. During the six months ended June 30, 2015 , we borrowed an additional $100.0 million . Borrowings accrue interest equal to adjusted LIBOR , plus a margin ranging from 0.90% to 1.80% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2015 was 1.15% per annum. Including the impact of the interest rate swaps associated with our unsecured term loan, the interest rate was 1.56% per annum, based on our current credit rating. The unsecured term loan matures on January 31, 2019 and includes a one -year extension, at the option of the borrower, subject to certain conditions.
$155.0 Million Unsecured Term Loan
As of June 30, 2015 , HTALP had a $155.0 million unsecured term loan outstanding that is guaranteed by HTA. The loan matures on July 19, 2019 and the interest rate thereon is equal to LIBOR, plus a margin ranging from 1.55% to 2.40% per annum based on our credit rating. The margin associated with our borrowings as of June 30, 2015 was 1.70% per annum. We have interest rate swaps in place that fix the interest rate at 2.99% per annum, based on our current credit rating. The maximum principal amount under this unsecured term loan may be increased by us, subject to such additional financing being provided by our existing lender.

16

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

$300.0 Million Unsecured Senior Notes due 2021
As of June 30, 2015 , HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and mature on July 15, 2021 . The unsecured senior notes are registered under the Securities Act of 1933, as amended (the “Securities Act”), bear interest at 3.375% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.205% of the principal amount thereof, with an effective yield to maturity of 3.50% per annum.
$300.0 Million Unsecured Senior Notes due 2023
As of June 30, 2015 , HTALP had $300.0 million of unsecured senior notes outstanding that are guaranteed by HTA and mature on April 15, 2023 . The unsecured senior notes are registered under the Securities Act, bear interest at 3.70% per annum and are payable semi-annually. The unsecured senior notes were offered at 99.186% of the principal amount thereof, with an effective yield to maturity of 3.80% per annum.
Fixed and Variable Rate Mortgages
As of June 30, 2015 , HTALP and its subsidiaries had fixed and variable rate mortgages with intere st rates ranging from 1.64% to 6.49%  per annum and a weighted average interest rate of 5.33%  per annum. Including the impact of the interest rate swap associated with our variable rate mortgage, the weighted average interest rate was 5.60% per annum.
Future Debt Maturities
The following table summarizes the debt maturities and scheduled principal repayments of our indebtedness as of June 30, 2015 (in thousands):
Year
 
Amount
2015
 
$
10,802

2016
 
69,657

2017
 
116,626

2018
 
14,429

2019
 
464,280

Thereafter
 
963,908

Total
 
$
1,639,702

The above scheduled debt maturities do not include the extension available to us under the Unsecured Credit Agreement as discussed above.
We are required by the terms of our applicable debt agreements to meet various affirmative and negative covenants that we believe are customary for these types of facilities, such as limitations on the incurrence of debt by us and our subsidiaries that own unencumbered assets, limitations on the nature of HTALP ’s business, and limitations on distributions by HTALP and its subsidiaries that own unencumbered assets. Our debt agreements also impose various financial covenants on us, such as a maximum ratio of total indebtedness to total asset value, a minimum ratio of EBITDA to fixed charges, a minimum tangible net worth covenant, a maximum ratio of unsecured indebtedness to unencumbered asset value, rent coverage ratios and a minimum ratio of unencumbered Net Operating Income (“NOI”) to unsecured interest expense. As of June 30, 2015 , we believe that we were in compliance with all such financial covenants and reporting requirements. In addition, certain of our debt agreements include events of default provisions that we believe are customary for these types of facilities, including restricting HTA from making dividend distributions to its stockholders in the event HTA is in default thereunder, except to the extent necessary for HTA to maintain its REIT status.
8. Derivative Financial Instruments
The following table lists the derivative financial instrument assets and (liabilities) held by us as of June 30, 2015 (in thousands):
Notional Amount
 
Index
 
Rate
 
Fair Value
 
Instrument
 
Maturity
$
100,000

 
LIBOR
 
0.86
%
 
$
(430
)
 
Swap
 
6/15/2016
50,000

 
LIBOR
 
1.39

 
62

 
Swap
 
7/17/2019
105,000

 
LIBOR
 
1.24

 
789

 
Swap
 
7/17/2019
26,486

 
LIBOR + 1.45%
 
4.98

 
(2,291
)
 
Swap
 
5/1/2020

17

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The following table lists the derivative financial instrument assets and (liabilities) held by us as of December 31, 2014 (in thousands):
Notional Amount
 
Index
 
Rate
 
Fair Value
 
Instrument
 
Maturity
$
100,000

 
LIBOR
 
0.86
%
 
$
(443
)
 
Swap
 
6/15/2016
50,000

 
LIBOR
 
1.39

 
317

 
Swap
 
7/17/2019
105,000

 
LIBOR
 
1.24

 
1,397

 
Swap
 
7/17/2019
26,874

 
LIBOR + 1.45%
 
4.98

 
(2,445
)
 
Swap
 
5/1/2020
As of June 30, 2015 and December 31, 2014 , the gross fair value of our derivative financial instruments was as follows (in thousands):
 
 
Asset Derivatives
 
Liability Derivatives
   
 
 
 
Fair Value
 
 
 
Fair Value
Derivatives Not Designated as Hedging Instruments:
 
Balance Sheet
Location
 
June 30, 2015
 
December 31, 2014
 
Balance Sheet
Location
 
June 30, 2015
 
December 31, 2014
Interest rate swaps
 
Receivables and other assets
 
$
851

 
$
1,714

 
Derivative financial instruments
 
$
2,721

 
$
2,888

There were no derivatives offset in our accompanying condensed consolidated balance sheets as of June 30, 2015 and December 31, 2014 . As of June 30, 2015 and December 31, 2014 , we had derivatives subject to enforceable master netting arrangements which allowed for net cash settlement with the respective counterparties (in thousands):
 
June 30, 2015
 
December 31, 2014
 
Gross Amounts
 
Amounts Subject to Enforceable Master Netting Arrangements
 
Net Amounts
 
Gross Amounts
 
Amounts Subject to Enforceable Master Netting Arrangements
 
Net Amounts
Asset derivatives
$
851

 
$
—

 
$
851

 
$
1,714

 
$
—

 
$
1,714

Liability derivatives
2,721

 
—

 
2,721

 
2,888

 
—

 
2,888

We have agreements with each of our interest rate swap derivative counterparties that contain a provision whereby if we default on certain of our unsecured indebtedness, then our counterparties could declare us in default on our interest rate swap derivative obligations resulting in an acceleration of the indebtedness. In addition, we are exposed to credit risk in the event of non-performance by our derivative counterparties. We believe we mitigate the credit risk by entering into agreements with credit-worthy counterparties. We record counterparty credit risk valuation adjustments on interest rate swap derivative assets in order to properly reflect the credit quality of the counterparty. In addition, our fair value of interest rate swap derivative liabilities is adjusted to reflect the impact of our credit quality. As of June 30, 2015 , there have been no termination events or events of default related to our interest rate swaps.
9. Stockholders’ Equity and Partners’ Capital
HTALP ’s partnership agreement provides that it will distribute cash flows from operations and net sale proceeds to its partners in accordance with their overall ownership interests at such times and in such amounts as the general partner determines. Dividend distributions are made such that a holder of one partnership unit in HTALP will receive distributions from HTALP in an amount equal to the dividend distributions paid to the holder of one share of HTA’s common stock. In addition, for each share of common stock issued or redeemed by HTA, HTALP issues or redeems a corresponding number of partnership units.
Common Stock Offerings
On February 28, 2014 , HTA amended the at-the-market (“ATM”) offering program of its common stock with an aggregate sales price of up to $300.0 million , primarily to add sales agents to the program. During the six months ended June 30, 2015 , HTA did not issue and sell any shares of its common stock under the ATM offering program and as of June 30, 2015 , $256.6 million remained available for issuance under the ATM. In July 2015 , HTA issued and sold 1,800,000 shares of common stock, at an average price of $25.00 per share.

18

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

Common Stock Dividends
See our accompanying condensed consolidated statements of operations for the dividends declared during three and six months ended June 30, 2015 and 2014 .
Incentive Plan
HTA’s Amended and Restated 2006 Incentive Plan (the “Plan”) permits the grant of incentive awards to our employees, officers, non-employee directors and consultants as selected by our Board of Directors. The Plan authorizes the granting of awards in any of the following forms: options; stock appreciation rights; restricted stock; restricted or deferred stock units; performance awards; dividend equivalents; other stock-based awards, including units in HTALP ; and cash-based awards. Subject to adjustment as provided in the Plan, the aggregate number of awards reserved and available for issuance under the Plan is 5,000,000 . As of June 30, 2015 , there were 2,135,810 awards available for grant under the Plan.
LTIP Units
Awards under the LTIP consist of Series C units in HTALP , and are subject to the achievement of certain performance and market conditions in order to vest. Once vested, the Series C units are converted into common units of HTALP , which may be converted into shares o f HTA’s common stock. T he LTIP awards were fully expensed in 2013, except for 225,000 units with a grant date fair value of $20.00 per unit that would only vest in the eve nt of a change in control prior to May 16, 2015. These units were forfeited in May 2015.
Restricted Common Stock
For the three and six months ended June 30, 2015 , we recognized compensation expense of $1.2 million and $3.1 million , respectively, which was recorded in general and administrative expenses. For the three and six months ended June 30, 2014 , we recognized compensation expense of $0.9 million and $2.3 million , respectively, which was recorded in general and administrative expenses.
As of June 30, 2015 , there was $5.5 million of unrecognized compensation expense net of estimated forfeitures, which will be recognized over a remaining weighted average period of 1.8 years.
The following is a summary of the activity in our restricted common stock during 2015 :
 
Restricted Common Stock
 
Weighted
Average Grant
Date Fair Value
Balance as of December 31, 2014
463,050

 
$
20.90

Granted
174,948

 
26.95

Vested
(114,529
)
 
21.89

Forfeited
(19,898
)
 
22.75

Balance as of June 30, 2015
503,571

 
$
22.63

10. Fair Value of Financial Instruments
Financial Instruments Reported at Fair Value - Recurring
The table below presents our assets and liabilities measured at fair value on a recurring basis as of June 30, 2015 , aggregated by the applicable Level in the fair value hierarchy (in thousands):
 
 
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1 )
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
 
Derivative financial instruments
 
$
—

 
$
851

 
$
—

 
$
851

Liabilities:
 
 
 
 
 
 
 
 
Derivative financial instruments
 
$
—

 
$
2,721

 
$
—

 
$
2,721


19

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

The table below presents our assets and liabilities measured at fair value on a recurring basis as of December 31, 2014 , aggregated by the applicable Level in the fair value hierarchy (in thousands):
 
 
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1 )
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
 
Derivative financial instruments
 
$
—


$
1,714


$
—

 
$
1,714

Liabilities:
 
 
 
 
 
 
 
 
Derivative financial instruments
 
$
—

 
$
2,888

 
$
—

 
$
2,888

Financial Instruments Reported at Fair Value - Non-Recurring
The table below presents our assets measured at fair value on a non-recurring basis as of June 30, 2015 , aggregated by the applicable Level in the fair value hierarchy (in thousands). There were no assets measured at fair value on a non-recurring basis in 2014.
 
 
Quoted Prices in
Active Markets for
Identical Assets
and Liabilities
(Level 1 )
 
Significant Other
Observable Inputs
(Level 2)
 
Significant
Unobservable Inputs
(Level 3)
 
Total
Assets:
 
 
 
 
 
 
 
 
MOB (1)
 
$
—

 
$
973

 
$
—

 
$
973

 
 
 
 
 
 
 
 
 
(1) During the three months ended June 30, 2015, we recognized a $1.7 million impairment charge to the carrying value of a MOB. The estimate of fair value as of June 30, 2015 was based upon a pending sales agreement on this MOB. In July 2015, we completed the disposition of this MOB.
There have been no transfers of assets or liabilities between Levels. We will record any such transfers at the end of the reporting period in which a change of event occurs that results in a transfer. Although we have determined that the majority of the inputs used to value our interest rate swap derivatives fall within Level 2 of the fair value hierarchy, the credit valuation adjustments associated with these instruments utilize Level 3 inputs, such as estimates of current credit spreads to evaluate the likelihood of default by us and our counterparties. However, we have assessed the significance of the impact of the credit valuation adjustments on the overall valuation of our interest rate swap derivative positions and have determined that the credit valuation adjustments are not significant to their overall valuation. As a result, we have determined that our interest rate swap derivative valuations in their entirety are classified in Level 2 of the fair value hierarchy.  
Financial Instruments Disclosed at Fair Value
We consider the carrying values of cash and cash equivalents, accounts and other receivables, restricted cash and escrow deposits and accounts payable and accrued liabilities to approximate fair value for these financial instruments because of the short period of time between origination of the instruments and their expected realization. All of these financial instruments are considered Level 2.
The fair value of debt is estimated using borrowing rates available to us with similar terms and maturities which is considered a Level 2 input. As of June 30, 2015 , the fair value of the debt was $1,665.2 million compared to the carrying value of $1,639.0 million . As of December 31, 2014 , the fair value of the debt was $1,447.4 million compared to the carrying value of $1,412.5 million .

20

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

11. Per Share Data of HTA
HTA includes unvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents as “participating securities” pursuant to the two-class method. The resulting classes are our common stock and restricted stock. For the three and six months ended June 30, 2015 and 2014 , all of HTA’s earnings were distributed and the calculated earnings per share amount would be the same for all classes.
The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per share of HTA common stock for the three and six months ended June 30, 2015 and 2014 (in thousands, except per share data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Numerator:
 
 
 
 
 
 
 
Net income
$
9,488

 
$
2,883

 
$
16,430

 
$
8,317

Net income attributable to noncontrolling interests
(196
)
 
(28
)
 
(334
)
 
(170
)
Net income attributable to common stockholders
$
9,292

 
$
2,855

 
$
16,096

 
$
8,147

Denominator: (1)
 
 
 
 
 
 
 
Weighted average number of shares outstanding - basic
125,194

 
119,012

 
125,184

 
118,829

Dilutive shares
1,930

 
1,263

 
1,930

 
1,265

Weighted average number of shares outstanding - diluted
127,124

 
120,275

 
127,114

 
120,094

Earnings per common share - basic (1)
 
 
 
 
 
 
 
Net income attributable to common stockholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Earnings per common share - diluted (1)
 
 
 
 
 
 
 
Net income attributable to common stockholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

 
 
 
 
 
 
 
 
(1) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
12. Per Unit Data of HTALP
The following is the reconciliation of the numerator and denominator used in basic and diluted earnings per unit of HTALP for the three and six months ended June 30, 2015 and 2014 (in thousands, except per unit data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Numerator:
 
 
 
 
 
 
 
Net income
$
9,488

 
$
2,883

 
$
16,430

 
$
8,317

Net income attributable to noncontrolling interests
(24
)
 
(40
)
 
(57
)
 
(78
)
Net income attributable to common unitholders
$
9,464

 
$
2,843

 
$
16,373

 
$
8,239

Denominator:   (1)
 
 
 
 
 
 
 
Weighted average number of units outstanding - basic
127,203

 
120,534

 
127,266

 
120,353

Dilutive units
—

 
—

 
—

 
—

Weighted average number of units outstanding - diluted
127,203

 
120,534

 
127,266

 
120,353

Earnings per common unit - basic: (1)
 
 
 
 
 
 
 
Net income attributable to common unitholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

Earnings per common unit - diluted: (1)
 
 
 
 
 
 
 
Net income attributable to common unitholders
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

 
 
 
 
 
 
 
 
(1) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.

21

HEALTHCARE TRUST OF AMERICA, INC. AND HEALTHCARE TRUST OF AMERICA HOLDINGS, LP
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS – (Continued)

13. Supplemental Cash Flow Information
The following is the supplemental cash flow information for the six months ended June 30, 2015 and 2014 (in thousands):
 
Six Months Ended June 30,
 
2015
 
2014
Interest paid
$
26,684

 
$
21,688

Income taxes paid
541

 
738

 
 
 
 
Supplemental Disclosure of Noncash Activities:
 
 
 
Investing Activities:
 
 
 
Accrued capital expenditures
$
2,839

 
$
454

The following represents the significant increase (decrease) in certain assets and liabilities in connection with our acquisitions:
 
 
 
Debt and interest rate swaps
$
—

 
$
88,845

Financing Activities:
 
 
 
Dividend distributions declared, but not paid
$
36,307

 
$
34,365


22


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
The use of the words “we,” “us” or “our” refers to HTA and HTALP , collectively.
The following discussion should be read in conjunction with our condensed consolidated financial statements and notes appearing elsewhere in this Quarterly Report on Form 10-Q, as well as with the audited consolidated financial statements, accompanying notes and Management’s Discussion and Analysis of Financial Condition and Results of Operations included in our 2014 Annual Report on Form 10-K. Such condensed consolidated financial statements and information have been prepared to reflect HTA’s and HTALP ’s financial position as of June 30, 2015 and December 31, 2014 , together with results of operations and cash flows for the three and six months ended June 30, 2015 and 2014 .
The information set forth below is intended to provide readers with an understanding of our financial condition, changes in financial condition and results of operations.
•
Forward-Looking Statements;
•
Executive Summary;
•
Company Highlights;
•
Critical Accounting Policies;
•
Recently Issued or Adopted Accounting Pronouncements;
•
Factors Which May Influence Results of Operations;
•
Results of Operations;
•
Non-GAAP Financial Measures;
•
Liquidity and Capital Resources;
•
Commitments and Contingencies;
•
Debt Service Requirements;
•
Off-Balance Sheet Arrangements;
•
Inflation; and
•
Federal Income Tax Changes and Updates for Incorporation in Existing Registration Statements.
Forward-Looking Statements
Certain statements contained in this Quarterly Report on Form 10-Q constitute forward-looking statements within the meaning of the safe harbor from civil liability provided for such statements by the Private Securities Litigation Reform Act of 1995 (set forth in Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended (“Exchange Act”)). Such statements include, in particular, statements about our plans, strategies and prospects and estimates regarding future MOB market performance. Additionally, such statements are subject to certain risks and uncertainties, as well as known and unknown risks, which could cause actual results to differ materially and in adverse ways from those projected or anticipated. Therefore, such statements are not intended to be a guarantee of our performance in future periods. Forward-looking statements are generally identifiable by the use of such terms as “expect,” “project,” “may,” “should,” “could,” “would,” “intend,” “plan,” “anticipate,” “estimate,” “believe,” “continue,” “opinion,” “predict,” “potential,” “pro forma” or the negative of such terms and other comparable terminology. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date this Quarterly Report on Form 10-Q is filed with the SEC. We cannot guarantee the accuracy of any such forward-looking statements contained in this Quarterly Report on Form 10-Q, and we do not intend to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Any such forward-looking statements reflect our current views about future events, are subject to unknown risks, uncertainties, and other factors, and are based on a number of assumptions involving judgments with respect to, among other things, future economic, competitive and market conditions, all of which are difficult or impossible to predict accurately. To the extent that our assumptions differ from actual results, our ability to meet such forward-looking statements, including our ability to generate positive cash flow from operations, provide dividends to stockholders and maintain the value of our real estate properties, may be significantly hindered. Factors that might impair our ability to meet such forward-looking statements include, without limitation, those discussed in Part I, Item 1A - Risk Factors in our 2014 Annual Report on Form 10-K, which is incorporated herein.

23

Table of Contents

Forward-looking statements express expectations of future events. All forward-looking statements are inherently uncertain as they are based on various expectations and assumptions concerning future events and they are subject to numerous known and unknown risks and uncertainties that could cause actual events or results to differ materially from those projected. Due to these inherent uncertainties, our stockholders are urged not to place undue reliance on forward-looking statements. Forward-looking statements speak only as of the date made. In addition, we undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to projections over time, except as required by law.
These risks and uncertainties should be considered in evaluating forward-looking statements and undue reliance should not be placed on such statements. Additional information concerning us and our business, including additional factors that could materially affect our financial results, is included herein and in our other filings with the SEC.
Executive Summary
HTA is one of the largest publicly-traded REITs focused on MOBs in the U.S. based on GLA. HTA conducts substantially all of its operations through HTALP . We are primarily focused on acquiring, owning and operating high quality MOBs that are predominantly located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. Our primary objective is to maximize stockholder value with disciplined growth through strategic investments and to provide an attractive risk-adjusted return for our stockholders by consistently increasing our cash flow. In pursuing this objective we: (i) generate internal growth through proactive asset management, leasing and property management; (ii) target accretive investments in MOBs that are on the campuses of, or aligned with, healthcare systems and located in markets with attractive demographics that complement our existing portfolio; and (iii) actively manage our balance sheet to maintain flexibility with low leverage.
Since 2006, we have invested $3.6 billion to create a portfolio of MOBs and other healthcare assets totaling approximately 15.4 million square feet of GLA throughout the U.S. Approximately 96% of our portfolio, based on GLA, is located on the campuses of, or aligned with, nationally or regionally recognized healthcare systems. We continue to focus on building relationships with strong tenants and healthcare systems that are leaders in their markets. The leased rate for our portfolio was 91.7% (includes leases which have been executed, but which have not yet commenced) and the occupancy rate was 91.1% as of June 30, 2015 . Approximately 60% of our annualized base rent as of June 30, 2015 was derived from tenants that have (or whose parent companies have) a credit rating from a nationally recognized rating agency.
Our portfolio is diversified geographically across 28 states, with no state having more than 13% of our total GLA as of June 30, 2015 . We are concentrated in locations that we have determined to be strategic based on demographic trends and projected demand for MOBs, and we expect to continue to invest in these markets. We have concentrations in the following key markets: Albany, Atlanta, Boston, Charleston, Dallas, Denver, Greenville, Honolulu, Houston, Indianapolis, Miami, Orlando, Phoenix, Pittsburgh, Raleigh, Tampa and White Plains.
Company Highlights
Portfolio Operating Performance
•
For the three months ended June 30, 2015 , we had net income of $9.5 million , compared to $2.9 million for the three months ended June 30, 2014 . For the six months ended June 30, 2015 , we had net income of $16.4 million , compared to $8.3 million for the six months ended June 30, 2014 .
•
For the three months ended June 30, 2015 , HTA’s Normalized FFO was $0.38 per diluted share, or $48.5 million , an increase of $0.02 per diluted share, or 6% , compared to the three months ended June 30, 2014 . For the three months ended June 30, 2015 , HTALP ’s Normalized FFO was $0.38 per diluted unit, or $48.5 million , an increase of $0.02 per diluted unit, or 6% , compared to the three months ended June 30, 2014 .
•
For the six months ended June 30, 2015 , HTA’s Normalized FFO was $0.75 per diluted share, or $95.2 million , an increase of $0.03 per diluted share, or 4% , compared to the six months ended June 30, 2014 . For the six months ended June 30, 2015 , HTALP ’s Normalized FFO was $0.75 per diluted unit, or $95.2 million , an increase of $0.04 per diluted unit, or 6% , compared to the six months ended June 30, 2014 .
•
For additional information on Normalized FFO, see “FFO and Normalized FFO” below, which includes a reconciliation to net income attributable to common stockholders/unitholders and an explanation of why we present this non-GAAP financial measure.
•
For the three months ended June 30, 2015 , our total revenue increased 10.8% , or $9.6 million , to $99.3 million , compared to the three months ended June 30, 2014 . For the six months ended June 30, 2015 , our total revenue increased 9.3% , or $16.9 million , to $197.8 million , compared to the six months ended June 30, 2014 .

24

Table of Contents

•
For the three months ended June 30, 2015 , our NOI increased 11.9% , or $7.5 million , to $70.1 million , compared to the three months ended June 30, 2014 . For the six months ended June 30, 2015 , our NOI increased 10.9% , or $13.6 million , to $137.9 million , compared to the six months ended June 30, 2014 .
•
For the three months ended June 30, 2015 , our Same-Property Cash NOI increased 3.0% , or $1.7 million , to $58.0 million , compared to the three months ended June 30, 2014 . For the six months ended June 30, 2015 , our Same-Property Cash NOI increased 3.0% , or $3.3 million , to $115.1 million , compared to the six months ended June 30, 2014 .
•
For additional information on NOI and Same-Property Cash NOI, see “NOI, Cash NOI and Same-Property Cash NOI” below, which includes a reconciliation to net income and an explanation of why we present these non-GAAP financial measures.
Internal Growth Through Proactive Asset Management Leasing and Property Management
•
As of June 30, 2015 , our leased rate (includes leases which have been executed, but which have not yet commenced) was 91.7% by GLA and our occupancy rate was 91.1% by GLA.
•
We entered into new and renewal leases on approximately 291,000 and 476,000 square feet of GLA during the three and six months ended June 30, 2015 , respectively.
•
Tenant retention for the Same-Property portfolio was 85% for the quarter and 82% for the year-to-date, which we believe is indicative of our commitment to maintaining buildings in desirable locations and fostering strong tenant relationships. Tenant retention is calculated by taking the sum of the total GLA of tenants that renew an expiring lease divided by the total GLA of expiring leases.
Relationship-Focused Strategy
We have been one of the most active investors in the medical office sector over the last eight years and have developed significant industry relationships with health systems, physician practices, regional medical office developers and management firms.
•
We have acquired $225.5 million of MOBs during the six months ended June 30, 2015 , an increase in our portfolio size by approximately 6.8% based on purchase price.
•
All of our acquisitions during the six months ended June 30, 2015 were either on the campuses of, or aligned with, nationally and regionally recognized healthcare systems. The leased rate at closing of these acquired properties was 99% .
•
All of our acquisitions during the six months ended June 30, 2015 were located in our key markets of Atlanta, Boston, Charleston, Indianapolis and Raleigh.
Financial Strategy and Balance Sheet Flexibility
•
As of June 30, 2015 , we had total liquidity of $631.1 million , including cash and cash equivalents of $16.6 million and $614.5 million available on our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit). Our leverage ratio of debt to capitalization was 35.0% .
•
In February 2015, we amended our Unsecured Credit Agreement. The amendment added an additional lender and increased the amount available under the unsecured revolving credit facility by $50.0 million to $850.0 million. The other existing terms of the Unsecured Credit Agreement were unchanged.
Critical Accounting Policies
The complete list of our critical accounting policies was disclosed in our 2014 Annual Report on Form 10-K. There have been no material changes to our critical accounting policies as disclosed therein.
Recently Issued or Adopted Accounting Pronouncements
See Note 2 to our accompanying condensed consolidated financial statements for a discussion of recently issued or adopted accounting pronouncements.
Factors Which May Influence Results of Operations
We are not aware of any material trends or uncertainties, other than national economic conditions affecting real estate generally and the risk factors previously listed in Part I, Item 1A - Risk Factors, in our 2014 Annual Report on Form 10-K, that may reasonably be expected to have a material impact, favorable or unfavorable, on revenues or income from the acquisition, management and operation of our properties.

25

Table of Contents

Rental Income
The amount of rental income generated by our properties depends principally on our ability to maintain the occupancy rates of currently leased space and to lease currently available space and space that will become available from unscheduled lease terminations at the then applicable rental rates. Negative trends in one or more of these factors could adversely affect our rental income in future periods.
Acquisitions and Dispositions
During the six months ended June 30, 2015 , we had acquisitions with an aggregate purchase price of $225.5 million and no dispositions. The following is a brief description of each of our acquisitions:
•
In March 2015, we acquired two MOBs located in Atlanta, Georgia for $35.3 million. These buildings are located on the campus of or affiliated with WellStar (98% leased and had approximately 117,000 square feet of GLA).
•
In April 2015, we acquired a two MOBs located in Raleigh, North Carolina for $18.7 million. These buildings are affiliated with Cary Orthopedics (100% leased and approximately 67,000 square feet of GLA).
•
In April 2015, we acquired a MOB located in Indianapolis, Indiana for $38.1 million. This building is affiliated with Community Health Network (96% leased and approximately 126,000 square feet of GLA).
•
In May 2015, we acquired a MOB located in Charleston, South Carolina for $10.6 million. This building is affiliated with Medical University of South Carolina (100% leased and approximately 39,000 square feet of GLA).
•
In May 2015, we acquired a MOB located in Raleigh, North Carolina for $21.4 million. This building is affiliated with Rex Healthcare (100% leased and approximately 64,000 square feet of GLA).
•
In June 2015, we acquired a MOB located in Boston, Massachusetts for $101.5 million. This building was located on the joint campus of Boston University and Boston Medical Center (100% leased and approximately 161,000 square feet of GLA).
During the six months ended June 30, 2014 , we had acquisitions with an aggregate purchase price of $211.5 million and no dispositions. The amount of any future acquisitions or dispositions could have a significant impact on our results of operations in future periods.
Results of Operations
Comparison of the Three and Six Months Ended June 30, 2015 and 2014
As of June 30, 2015 , we owned and operated approximately 15.4 million square feet of GLA, with a 91.7% leased rate (includes leases which have been executed, but which have not yet commenced) and a 91.1% occupancy rate. As of June 30, 2014 , we owned and operated approximately 14.6 million square feet of GLA, with a 91.5% leased rate (includes leases which have been executed, but which have not yet commenced) and a 90.9% occupancy rate. All explanations are applicable to both HTA and HTALP unless otherwise noted.
NOI and Same-Property Cash NOI
NOI increased $7.5 million to $70.1 million for the three months ended June 30, 2015 , compared to the three months ended June 30, 2014 . NOI increased $13.6 million to $137.9 million for the six months ended June 30, 2015 , compared to the six months ended June 30, 2014 . The increases were primarily due to the $8.4 million and $16.3 million of additional NOI from our 2014 and 2015 acquisitions for the three and six months ended June 30, 2015 , respectively, partially offset by a decrease in NOI as a result of the buildings we sold during the third and fourth quarter of 2014 , a reduction of interest income from the real estate notes receivable paid off by the borrowers during 2014 and a reduction in straight-line rent.
Same-Property Cash NOI increased $1.7 million to $58.0 million for the three months ended June 30, 2015 , compared to the three months ended June 30, 2014 . Same-Property Cash NOI increased $3.3 million to $115.1 million for the six months ended June 30, 2015 , compared to the six months ended June 30, 2014 . The increases were primarily the result of rent escalations, an increase in average occupancy and improved operating efficiencies.

26

Table of Contents

Rental Income
For the three and six months ended June 30, 2015 and 2014 , rental income was comprised of the following (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Contractual rental income
$
96,039

 
$
86,483

 
$
191,282

 
$
173,868

Straight-line rent and amortization of above/below market leases
2,085

 
1,464

 
4,216

 
3,459

Other operating revenue
1,119

 
999

 
2,197

 
2,071

Total
$
99,243

 
$
88,946

 
$
197,695

 
$
179,398

Contractual rental income, which includes expense reimbursements, increased $9.6 million for the three months ended June 30, 2015 , compared to the three months ended June 30, 2014 . The increase was primarily due to $11.2 million of additional contractual rental income from our 2014 and 2015 acquisitions (including properties owned in both periods) and contractual rent increases, partially offset by a decrease in contractual rent as a result of the buildings we sold during the third and fourth quarter of 2014 . For the three months ended June 30, 2015 , we entered into new and renewal leases of approximately 291,000 square feet of GLA. The new and renewal leases commenced at an average starting annual base rent of $22.85 per square foot of GLA compared to an average ending annual base rent of $22.96 per square foot of GLA for expiring leases. Lease rates can vary between markets and rates that are considered above or below current market rent may change overtime. Leases that expired during the quarter had rents that we believed were generally at market rates. Generally, leasing concessions vary depending on lease type and term. For the three months ended June 30, 2015 , new leases had tenant improvements, leasing commissions and tenant concessions of $27.96 , $2.02 and $4.55 per square foot of GLA, respectively, compared to $19.32 , $5.46 and $4.50 per square foot of GLA, respectively, for the three months ended June 30, 2014 . Average term for new leases executed was 7.3 years and 6.6 years for the three months ended June 30, 2015 and 2014 , respectively. Renewal leases had tenant improvements, leasing commissions and tenant concessions of $6.71 , $0.99 and $1.83 per square foot of GLA, respectively, for the three months ended June 30, 2015 , compared to $6.03 , $2.81 and $2.06 per square foot of GLA, respectively, for the three months ended June 30, 2014 . Average term for renewal leases executed was 6.8 years and 4.5 years for the three months ended June 30, 2015 and 2014 , respectively.
Contractual rental income, which includes expense reimbursements, increased $17.4 million for the six months ended June 30, 2015 , compared to the six months ended June 30, 2014 . The increase was primarily due to $21.4 million of additional contractual rental income from our 2014 and 2015 acquisitions (including properties owned in both periods) and contractual rent increases, partially offset by a decrease in contractual rent as a result of the buildings we sold during the third and fourth quarter of 2014 . For the six months ended June 30, 2015 , we entered into new and renewal leases of approximately 476,000 square feet of GLA. The new and renewal leases commenced at an average starting annual base rent of $22.64 per square foot of GLA compared to an average ending annual base rent of $22.61 per square foot of GLA for expiring leases. Lease rates can vary between markets and rates that are considered above or below current market rent may change overtime. Leases that expired thus far in 2015 had rents that we believed were generally at market rates. Generally, leasing concessions vary depending on lease type and term. For the six months ended June 30, 2015 , new leases had tenant improvements, leasing commissions and tenant concessions of $25.06 , $3.23 and $5.16 per square foot of GLA, respectively, compared to $18.30 , $5.05 and $5.08 per square foot of GLA, respectively, for the six months ended June 30, 2014 . Average term for new leases executed was 7.3 years and 6.7 years for the six months ended June 30, 2015 and 2014 , respectively. Renewal leases had tenant improvements, leasing commissions and tenant concessions of $5.52 , $0.94 and $1.34 per square foot of GLA, respectively, for the six months ended June 30, 2015 , compared to $5.45 , $2.57 and $1.97 per square foot of GLA, respectively, for the six months ended June 30, 2014 . Average term for renewal leases executed was 6.0 years and 4.3 years for the six months ended June 30, 2015 and 2014 , respectively.
Rental Expenses
For the three months ended June 30, 2015 and 2014 , rental expenses attributable to our properties were $29.2 million and $27.1 million , respectively. For the six months ended June 30, 2015 and 2014 , rental expenses attributable to our properties were $59.9 million and $56.7 million , respectively. The increase in rental expenses was primarily due to $3.6 million and $6.8 million of additional rental expenses associated with our 2014 and 2015 acquisitions for the three and six months ended June 30, 2015 , respectively, partially offset by improved operating efficiencies and a decrease in rental expenses as a result of the buildings we sold during the third and fourth quarter of 2014 .

27

Table of Contents

General and Administrative Expenses
For the three months ended June 30, 2015 and 2014 , general and administrative expenses were $6.2 million and $5.9 million , respectively. For the six months ended June 30, 2015 and 2014 , general and administrative expenses were $12.8 million and $12.2 million , respectively. General and administrative expenses include such costs as salaries, corporate overhead and professional fees, among other items.
Acquisition-Related Expenses
For the three months ended June 30, 2015 and 2014 , acquisition-related expenses were $1.1 million and $4.9 million , respectively. For the six months ended June 30, 2015 and 2014 , acquisition-related expenses were $2.5 million and $5.8 million , respectively. The decrease in acquisition-related expenses was primarily due to lower closing costs incurred by us on our 2015 acquisitions.
Depreciation and Amortization Expense
For the three months ended June 30, 2015 and 2014 , depreciation and amortization expense was $38.1 million and $33.6 million , respectively. For the six months ended June 30, 2015 and 2014 , depreciation and amortization expense was $74.7 million and $68.5 million , respectively. The increase in depreciation and amortization expense was primarily due to the increase in the size of our portfolio.
Impairment Charge
For the three and six months ended June 30, 2015 , we recorded an impairment charge of $1.7 million associated with a MOB that was being marketed for sale. In July 2015, we completed the disposition of this building and a separate portfolio of MOBs for an aggregate gross sales price of $34.9 million . These dispositions did not meet the requirements to be classified as held for sale as of June 30, 2015, as due diligence was on-going and the completion of the sales were not reasonably assured as of the end of the quarter. We did not record any impairment charges in 2014.
Interest Expense and Net Change in Fair Value of Derivative Financial Instruments
Interest expense excluding the impact of the net change in fair value of derivative financial instruments increased by $1.8 million during the three months ended June 30, 2015 , compared to the same period in 2014 . The increase was primarily due to the issuance of $300.0 million of unsecured senior notes in June 2014 and additional borrowings on our unsecured revolving credit facility during 2015, partially offset by the decreased interest rate on our Unsecured Credit Agreement as a result of the amendments executed during 2014. During the three months ended June 30, 2015 , the fair market value of our derivatives increased $1.3 million , compared to a net decrease of $2.6 million during the three months ended June 30, 2014 .
Interest expense excluding the impact of the net change in fair value of derivative financial instruments increased by $2.9 million during the six months ended June 30, 2015 , compared to the same period in 2014 . The increase was primarily due to the issuance of $300.0 million of unsecured senior notes in June 2014 and additional borrowings on our unsecured revolving credit facility during 2015, partially offset by the decreased interest rate on our Unsecured Credit Agreement as a result of the amendments executed during 2014. During the six months ended June 30, 2015 , the fair market value of our derivatives decreased $0.7 million , compared to a net decrease of $3.4 million during the six months ended June 30, 2014 .
To achieve our objectives, we borrow at both fixed and variable rates. We also enter into derivative financial instruments, such as interest rate swaps, in order to mitigate our interest rate risk on a related financial instrument. We do not enter into derivative or interest rate transactions for speculative purposes. Derivatives not designated as hedges are not speculative and are used to manage our exposure to interest rate movements.
Non-GAAP Financial Measures
FFO and Normalized FFO
We compute FFO in accordance with the current standards established by the National Association of Real Estate Investment Trusts (“NAREIT”). NAREIT defines FFO, as net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP), excluding gains or losses from sales of real estate property and impairment write-downs of depreciable assets, plus real estate depreciation and amortization, and after adjustments for unconsolidated partnerships and joint ventures. We present this non-GAAP financial measure because we consider it an important supplemental measure of our operating performance and believe it is frequently used by securities analysts, investors and other interested parties in the evaluation of REITs. Historical cost accounting assumes that the value of real estate assets diminishes ratably over time. Since real asset values have historically risen or fallen based on market conditions, many industry investors have considered the presentation of operating results for real estate companies that use historical cost accounting to be insufficient by themselves. Because FFO excludes depreciation and amortization unique to real estate, among other items, it provides a perspective not immediately apparent from net income or loss attributable to common stockholders/unitholders.

28

Table of Contents

Our methodology for calculating FFO may be different from methods utilized by other REITs and, accordingly, may not be comparable to such other REITs. FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance, nor is it indicative of cash available to fund cash needs. FFO should be reviewed in connection with other GAAP measurements.
We also compute Normalized FFO, which excludes from FFO: (i) acquisition-related expenses; (ii) net gain or loss on change in fair value of derivative financial instruments; (iii) gain or loss on extinguishment of debt; (iv) noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA); and (v) other normalizing items. We present this non-GAAP financial measure because it allows for the comparison of our operating performance to other REITs and between periods on a consistent basis. Our methodology for calculating Normalized FFO may be different from the methods utilized by other REITs and, accordingly, may not be comparable to other REITs. Normalized FFO should not be considered as an alternative to net income or loss attributable to common stockholders/unitholders (computed in accordance with GAAP) as an indicator of our financial performance, nor is it indicative of cash available to fund cash needs. Normalized FFO should be reviewed in connection with other GAAP measurements.
The amounts included in the calculation of FFO and Normalized FFO are generally the same for HTALP and HTA, except for net income or loss attributable to common stockholders/unitholders, noncontrolling income or loss from partnership units included in diluted shares (only applicable to HTA) and the weighted average number of shares of HTA common stock or HTALP partnership units outstanding.
The following is the reconciliation of HTA’s FFO and Normalized FFO to net income attributable to common stockholders for the three and six months ended June 30, 2015 and 2014 (in thousands, except per share data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Net income attributable to common stockholders
$
9,292

 
$
2,855

 
$
16,096

 
$
8,147

Depreciation and amortization expense
37,752

 
33,602

 
74,032

 
68,544

Impairment
1,655

 
—

 
1,655

 
—

FFO attributable to common stockholders
$
48,699

 
$
36,457

 
$
91,783

 
$
76,691

Acquisition-related expenses
1,101

 
4,869

 
2,458

 
5,845

Net (gain) loss on change in fair value of derivative financial instruments
(1,314
)
 
2,580

 
696

 
3,421

Gain on extinguishment of debt
(121
)
 
(365
)
 
(121
)
 
(365
)
Noncontrolling income (loss) from partnership units included in diluted shares
172

 
(12
)
 
277

 
92

Other normalizing items
—

 
—

 
89

 
209

Normalized FFO attributable to common stockholders
$
48,537

 
$
43,529

 
$
95,182

 
$
85,893

 
 
 
 
 
 
 
 
Net income attributable to common stockholders per diluted share (1)
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

FFO adjustments per diluted share, net (1)
0.31

 
0.28

 
0.59

 
0.57

FFO attributable to common stockholders per diluted share (1)
$
0.38

 
$
0.30

 
$
0.72

 
$
0.64

Normalized FFO adjustments per diluted share, net (1)
0.00

 
0.06

 
0.03

 
0.08

Normalized FFO attributable to common stockholders per diluted share (1)
$
0.38

 
$
0.36

 
$
0.75

 
$
0.72

 
 
 
 
 
 
 
 
Weighted average number of diluted common shares outstanding (1)
127,124

 
120,275

 
127,114

 
120,094

 
 
 
 
 
 
 
 
(1) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.

29

Table of Contents

The following is the reconciliation of HTALP ’s FFO and Normalized FFO to net income attributable to common unitholders for the three and six months ended June 30, 2015 and 2014 (in thousands, except per unit data):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Net income attributable to common unitholders
$
9,464

 
$
2,843

 
$
16,373

 
$
8,239

Depreciation and amortization expense
37,752

 
33,602

 
74,032

 
68,544

Impairment
1,655

 
—

 
1,655

 
—

FFO attributable to common unitholders
$
48,871

 
$
36,445

 
$
92,060

 
$
76,783

Acquisition-related expenses
1,101

 
4,869

 
2,458

 
5,845

Net (gain) loss on change in fair value of derivative financial instruments
(1,314
)
 
2,580

 
696

 
3,421

Gain on extinguishment of debt
(121
)
 
(365
)
 
(121
)
 
(365
)
Other normalizing items
—

 
—

 
89

 
209

Normalized FFO attributable to common unitholders
$
48,537

 
$
43,529

 
$
95,182

 
$
85,893

 
 
 
 
 
 
 
 
Net income attributable to common unitholders per diluted unit (1)
$
0.07

 
$
0.02

 
$
0.13

 
$
0.07

FFO adjustments per diluted unit, net (1)
0.31

 
0.28

 
0.59

 
0.57

FFO attributable to common unitholders per diluted unit (1)
$
0.38

 
$
0.30

 
$
0.72

 
$
0.64

Normalized FFO adjustments per diluted unit, net (1)
0.00

 
0.06

 
0.03

 
0.07

Normalized FFO attributable to common unitholders per diluted unit (1)
$
0.38

 
$
0.36

 
$
0.75

 
$
0.71

 
 
 
 
 
 
 
 
Weighted average number of diluted common units outstanding (1)
127,203

 
120,534

 
127,266

 
120,353

 
 
 
 
 
 
 
 
(1) For the three and six months ended June 30, 2014, amounts have been adjusted retroactively to reflect a 1-for-2 reverse stock split effected December 15, 2014.
NOI, Cash NOI and Same-Property Cash NOI
NOI is a non-GAAP financial measure that is defined as net income or loss (computed in accordance with GAAP) before: (i) general and administrative expenses; (ii) acquisition-related expenses; (iii) depreciation and amortization expense; (iv) impairment; (v) interest expense and net change in fair value of derivative financial instruments; (vi) gain or loss on extinguishment of debt; and (vii) other income or expense. We believe that NOI provides an accurate measure of the operating performance of our operating assets because NOI excludes certain items that are not associated with the management of our properties. Additionally, we believe that NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. NOI should be reviewed in connection with other GAAP measurements.
Cash NOI is a non-GAAP financial measure which excludes from NOI: (i) straight-line rent adjustments, net; (ii) amortization of below and above market leases/leasehold interests, net; and (iii) lease termination fees. We believe that Cash NOI provides another measurement of the operating performance of our operating assets. Additionally, we believe that Cash NOI is a widely accepted measure of comparative operating performance of REITs. However, our use of the term Cash NOI may not be comparable to that of other REITs as they may have different methodologies for computing this amount. Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Cash NOI should be reviewed in connection with other GAAP measurements.
To facilitate the comparison of Cash NOI between periods, we calculate comparable amounts for a subset of our owned properties referred to as “Same-Property.” Same-Property Cash NOI excludes properties which have not been owned and operated during the entire span of all periods presented or are intended to be sold in the near term, notes receivable interest income and certain non-routine items. Same-Property Cash NOI should not be considered as an alternative to net income or loss (computed in accordance with GAAP) as an indicator of our financial performance. Same-Property Cash NOI should be reviewed in connection with other GAAP measurements.

30

Table of Contents

The following is the reconciliation of HTA’s and HTALP ’s NOI, Cash NOI and Same-Property Cash NOI to net income for the three and six months ended June 30, 2015 and 2014 (in thousands):
 
Three Months Ended June 30,
 
Six Months Ended June 30,
 
2015
 
2014
 
2015
 
2014
Net income
$
9,488

 
$
2,883

 
$
16,430

 
$
8,317

General and administrative expenses
6,224

 
5,903

 
12,799

 
12,202

Acquisition-related expenses
1,101

 
4,869

 
2,458

 
5,845

Depreciation and amortization expense
38,066

 
33,602

 
74,661

 
68,544

Impairment
1,655

 
—

 
1,655

 
—

Interest expense and net change in fair value of derivative financial instruments
13,665

 
15,729

 
30,034

 
29,819

Gain on extinguishment of debt
(121
)
 
(365
)
 
(121
)
 
(365
)
Other income
(4
)
 
(14
)
 
(19
)
 
(40
)
NOI
$
70,074

 
$
62,607

 
$
137,897

 
$
124,322

Straight-line rent adjustments, net
(2,066
)
 
(1,553
)
 
(4,085
)
 
(3,653
)
Amortization of below and above market leases/leasehold interests, net
572

 
607

 
1,152

 
1,275

Lease termination fees
—

 
—

 
(11
)
 
(13
)
Cash NOI
$
68,580

 
$
61,661

 
$
134,953

 
$
121,931

Notes receivable interest income
—

 
(564
)
 
—

 
(1,345
)
Non Same-Property Cash NOI
(10,599
)
 
(4,792
)
 
(19,850
)
 
(8,822
)
Same-Property Cash NOI (1)
$
57,981

 
$
56,305

 
$
115,103

 
$
111,764

 
 
 
 
 
 
 
 
(1) Same-Property includes 268 buildings for the three and six months ended June 30, 2015 and 2014.
Liquidity and Capital Resources
Our primary sources of cash include: (i) cash flow from operations; (ii) borrowings under our unsecured revolving credit facility; and (iii) proceeds from the issuances of debt and equity securities. During the next 12 months our primary uses of cash are expected to include: (i) acquisitions of MOBs and other facilities that serve the healthcare industry; (ii) capital expenditures; (iii) the payment of operating expenses; (iv) debt service payments including principal payments; and (v) paying dividends to our stockholders. We anticipate cash flow from operations, restricted cash and reserve accounts and our unsecured revolving credit facility, if needed, will be sufficient to fund our operating expenses, capital expenditures and dividends to stockholders. Acquisitions and maturing indebtedness may require funds from the issuance of debt and/or equity securities.
As of June 30, 2015 , we had liquidity of $631.1 million , including $614.5 million available on our unsecured revolving credit facility (includes the impact of $5.5 million of outstanding letters of credit) and $16.6 million of cash and cash equivalents.
As of June 30, 2015 , $256.6 million was available for issuance under our $300.0 million ATM program. In addition, we had unencumbered properties with a gross book value of $2.9 billion . The unencumbered properties may be used as collateral to secure additional financings in future periods or refinance our current debt as it becomes due. Our ability to raise funds from future debt and equity issuances is dependent on our investment grade credit ratings, general economic and market conditions and our operating performance.
When we acquire a property, we prepare a capital plan that contemplates the estimated capital needs of that investment. In addition to operating expenses, capital needs may also include costs of refurbishment, tenant improvements or other major capital expenditures. The capital plan for each investment will be adjusted through ongoing, regular reviews of our portfolio or as necessary to respond to unanticipated additional capital needs. As of June 30, 2015 , we estimate that our expenditures for capital improvements for the remainder of 2015 will range from $10 million to $15 million depending on leasing activity. As of June 30, 2015 , we had $8.9 million of restricted cash and reserve accounts for such capital expenditures. We cannot provide assurance, however, that we will not exceed these estimated expenditure levels.

31

Table of Contents

If we experience lower occupancy levels, reduced rental rates, reduced revenues as a result of asset sales, or increased capital expenditures and leasing costs compared to historical levels due to competitive market conditions for new and renewal leases, the effect would be a reduction of net cash provided by operating activities. If such a reduction of net cash provided by operating activities is realized, we may have a cash flow deficit in subsequent periods. Our estimate of net cash available is based on various assumptions which are difficult to predict, including the levels of our leasing activity and related leasing costs. Any changes in these assumptions could impact our financial results and our ability to fund working capital and unanticipated cash needs.
Cash Flows
The following is a summary of our cash flows for the six months ended June 30, 2015 and 2014 (in thousands):
 
Six Months Ended June 30,
 
 
 
2015
 
2014
 
Change
Cash and cash equivalents - beginning of period
$
10,413

 
$
18,081

 
$
(7,668
)
Net cash provided by operating activities
87,166

 
73,212

 
13,954

Net cash used in investing activities
(232,926
)
 
(119,686
)
 
(113,240
)
Net cash provided by financing activities
151,924

 
161,112

 
(9,188
)
Cash and cash equivalents - end of period
$
16,577

 
$
132,719

 
$
(116,142
)
Net cash provided by operating activities increased in 2015 primarily due to the impact of our 2014 and 2015 acquisitions. We anticipate cash flows from operating activities to increase as a result of contractual rent increases and continued leasing activity in our existing portfolio and as we continue to acquire more properties.
For the six months ended June 30, 2015 , net cash used in investing activities primarily related to the acquisition of real estate operating properties of $224.3 million and capital expenditures of $13.1 million . For the six months ended June 30, 2014 , net cash used in investing activities primarily related to the acquisition of real estate operating properties of $123.2 million and capital expenditures of $10.3 million , partially offset by $15.0 million from the collection of a note receivable. We anticipate cash flows used in investing activities to increase as we continue to acquire more properties.
For the six months ended June 30, 2015 , net cash provided by financing activities primarily related to net borrowings of $294.0 million on our Unsecured Credit Agreement, partially offset by dividends to holders of our common stock of $72.6 million and payments on our mortgage and term loans of $67.2 million . For the six months ended June 30, 2014 , net cash provided by financing activities primarily related to net proceeds from the issuance of unsecured senior notes of $297.6 million , partially offset by dividends to holders of our common stock of $68.2 million , net payments on our Unsecured Credit Agreement of $55.0 million and payments on our mortgage loans of $27.2 million .
Dividends
The amount of dividends HTA pays to its stockholders is determined by its Board of Directors, in its sole discretion, and is dependent on a number of factors, including funds available, our financial condition, capital expenditure requirements and annual dividend distribution requirements needed to maintain our status as a REIT under the Internal Revenue Code of 1986, as amended. HTA has paid dividends monthly or quarterly since February 2007 , and if our investments produce sufficient cash flow, we expect to continue to pay dividends to our stockholders. Because our cash available for dividend distributions in any year may be less than 90% of our taxable income for the year, we may obtain the necessary funds through borrowings, issuing new securities or selling assets to pay out enough of our taxable income to satisfy our dividend distribution requirement. HTA’s organizational documents do not establish a limit on dividends that may constitute a return of capital for federal income tax purposes. The dividend HTA pays to its stockholders is equal to the distributions received from HTALP in accordance with the terms of HTALP ’s partnership agreement. It is HTA’s intention to continue to pay dividends. However, HTA’s Board of Directors may reduce our dividend rate and HTA cannot guarantee the timing and amount of dividends that it may pay in the future, if any.
For the six months ended June 30, 2015 , HTA paid cash dividends of $72.6 million . In July 2015, HTA paid cash dividends of $36.3 million for the quarter ended June 30, 2015 .

32

Table of Contents

Financing
We have historically maintained a low leveraged balance sheet and intend to continue to maintain this structure over the long run. However, our total leverage may fluctuate on a short term basis as we execute our business strategy. As of June 30, 2015 , our leverage ratio of debt to capitalization was 35.0% .
As of June 30, 2015 , we had debt outstanding of $1.6 billion and the weighted average interest rate was 3.25%  per annum, inclusive of the impact of our interest rate swaps. The following is a summary of our unsecured and secured debt. See Note 7 to our accompanying condensed consolidated financial statements, for a further discussion of our debt.
Unsecured Revolving Credit Facility
As of June 30, 2015 , $614.5 million was available on our unsecured revolving credit facility. Our unsecured revolving credit facility matures in January 2020 . On February 11, 2015, we executed an amendment to the Unsecured Credit Agreement which added an additional lender and increased the amount available under the unsecured revolving credit facility by $50.0 million to total of $850.0 million . The other existing terms of the Unsecured Credit Agreement were unchanged.
Unsecured Term Loans
As of June 30, 2015 , we had $455.0 million of unsecured term loans outstanding comprised of a $300.0 million term loan under our Unsecured Credit Agreement and a $155.0 million term loan, both maturing in 2019. During the six months ended June 30, 2015 , we borrowed an additional $100.0 million on our term loan under our Unsecured Credit Agreement. The $300.0 million term loan includes a one-year extension, at the option of the borrower, subject to certain conditions.
Unsecured Senior Notes
As of June 30, 2015 , we had $300.0 million of unsecured senior notes that mature in July 2021 and $300.0 million of unsecured senior notes that mature in April 2023 .
Mortgage Loans
During the six months ended June 30, 2015 , we made payments of $67.2 million on our mortgage loans and we have $10.8 million of principal payments due on currently outstanding indebtedness during the remainder of 2015.
Commitments and Contingencies
There have been no material changes from the commitments and contingencies disclosed in our 2014 Annual Report on Form 10-K.
Debt Service Requirements
We are required by the terms of our applicable loan agreements to meet certain financial covenants, such as minimum net worth and liquidity, and reporting requirements, among others. As of June 30, 2015 , we believe that we were in compliance with all such covenants and we are not aware of any covenants that it is reasonably likely that we would not be able to meet.
Off-Balance Sheet Arrangements
As of and during the six months ended June 30, 2015 , we had no off-balance sheet arrangements.
Inflation
We are exposed to inflation risk as income from future long-term leases is the primary source of our cash flows from operations. There are provisions in the majority of our tenant leases that protect us from the impact of normal inflation. These provisions include rent escalations, reimbursement billings for operating expense pass-through charges and real estate tax and insurance reimbursements on a per square foot allowance. However, due to the long-term nature of our leases, among other factors, the leases may not reset frequently enough to cover inflation.

Federal Income Tax Changes and Updates for Incorporation in Existing Registration Statements
The following discussion updates the disclosures under “Material U.S. Federal Income Tax Considerations” in the prospectus dated December 21, 2012 contained in our Registration Statement on Form S-3 filed with the SEC on December 24, 2012, and in our other registration statements into which this Quarterly Report on Form 10-Q is incorporated by reference.

33

Table of Contents

The discussion under the heading “Additional U.S. Federal Income Tax Withholding Rules” is replaced in its entirety with the following:
“Sections 1471 through 1474 of the Code and the Treasury regulations promulgated thereunder (commonly referred to as “FATCA”) generally impose a 30% withholding tax on U.S. source dividends and, beginning January 1, 2017, gross proceeds from the sale or other disposition of stock or property that is capable of producing U.S. source dividends paid to (i) a foreign financial institution (as defined in Section 1471(d)(4) of the Code) unless such foreign financial institution agrees, pursuant to an agreement with the U.S. Treasury Department or otherwise, to collect and disclose certain information regarding its direct and indirect U.S. owners (which, for this purpose, can include certain debt and  equity holders of such foreign financial institution as well as the direct and indirect owners of financial accounts maintained by such institution) and satisfies certain other requirements, and (ii) certain other non-U.S. entities unless such entities provide the payor with information regarding certain direct and indirect U.S. owners of the entity, or certify that they have no such U.S. owners, and comply with certain other requirements.  Withholding under FATCA is imposed on payments to foreign financial institutions and other applicable payees whether they receive such payments in the capacity of an intermediary or for their own account.  Certain countries have entered into, and other countries are expected to enter into, agreements with the United States to facilitate the type of information reporting required under FATCA.  While the existence of such agreements will not eliminate the risk that payments in respect of our Class A common stock will be subject to the withholding described above, these agreements are expected to reduce the risk of the withholding for investors in (or indirectly holding our Class A common stock through financial institutions in) those countries.  Each non-U.S. stockholder and any U.S. stockholder holding our Class A common stock through a foreign financial institution is urged to consult its own tax advisor about the possible impact of these rules on their investment in our Class A common stock, and the entities through which they hold our Class A common stock, including, without limitation, the process and deadlines for meeting the applicable requirements to prevent the imposition of this 30% withholding of tax under FATCA.”
Item 3. Quantitative and Qualitative Disclosures About Market Risk
There were no material changes in the information regarding market risk that was provided in our 2014 Annual Report on Form 10-K. The table below presents, as of June 30, 2015 , the principal amounts of our fixed and variable debt and the weighted average interest rates excluding the impact of interest rate swaps by year of expected maturity to evaluate the expected cash flows and sensitivity to interest rate changes (in thousands, except interest rates):
 
Expected Maturity Date
 
2015
 
2016
 
2017
 
2018
 
2019
 
Thereafter
 
Total
Fixed rate debt 
$
10,553

 
$
69,133

 
$
116,062

 
$
13,821

 
$
8,625

 
$
707,270

 
$
925,464

Weighted average interest rate on fixed rate debt (per annum)
5.30
%
 
5.48
%
 
5.92
%
 
6.23
%
 
5.58
%
 
3.83
%
 
4.28
%
Variable rate debt
$
249

 
$
524

 
$
564

 
$
608

 
$
455,655

 
$
256,638

 
$
714,238

Weighted average interest rate on variable rate debt based on forward rates in effect as of June 30, 2015 (per annum)
1.68
%
 
2.20
%
 
2.94
%
 
3.48
%
 
3.75
%
 
3.71
%
 
1.44
%
Our total debt was $1.6 billion as of June 30, 2015 . We had fixed and variable rate debt with interest rates ranging from 1.24% to 6.49% per annum and a weighted average interest rate of 3.04% per annum as of June 30, 2015 , excluding the impact of interest rate swaps. We had $925.5 million (excluding net premium/discount) of fixed rate debt, or 56% of total debt, at a weighted average interest rate of 4.28% per annum, and $714.2 million (excluding net premium/discount) of variable rate debt, or 44% of total debt, at a weighted average interest rate of 1.44% per annum as of June 30, 2015 , excluding the impact of interest rate swaps.
As of June 30, 2015 , the fair value of our fixed rate debt was $944.8 million and the fair value of our variable rate debt was $720.4 million based upon prevailing market rates as of June 30, 2015 .
As of June 30, 2015 , we had interest rate swaps outstanding that effectively fix $281.5 million of our variable rate debt. Including the impact of these interest rate swaps, the effective rate on our variable rate and total debt is 1.90% and 3.25% per annum, respectively.
In addition to changes in interest rates, the value of our future properties is subject to fluctuations based on changes in local and regional economic conditions and changes in the creditworthiness of tenants, which may affect our ability to refinance our debt if necessary.

34

Table of Contents

Item 4. Controls and Procedures
Healthcare Trust of America, Inc.
HTA’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTA’s management, including HTA’s Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer, principal financial officer and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure.
As of June 30, 2015 , an evaluation was conducted by HTA under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer concluded that HTA’s disclosure controls and procedures were effective.
There were no changes in HTA’s internal control over financial reporting that occurred during the quarter ended June 30, 2015 that have materially affected, or are reasonably believed to be likely to materially affect, HTA’s internal control over financial reporting.
Healthcare Trust of America Holdings, LP
HTALP ’s management is responsible for establishing and maintaining disclosure controls and procedures that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to HTALP ’s management, including HTA’s Chief Executive Officer and Chief Financial Officer, who serve as our principal executive officer, principal financial officer and principal accounting officer, as appropriate, to allow timely decisions regarding required disclosure.
As of June 30, 2015 , an evaluation was conducted by HTALP under the supervision and with the participation of its management, including HTA’s Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, HTA’s Chief Executive Officer and the Chief Financial Officer, on behalf of HTA in its capacity as general partner of HTALP , concluded that HTALP ’s disclosure controls and procedures were effective.
There were no changes in HTALP ’s internal control over financial reporting that occurred during the quarter ended June 30, 2015 that have materially affected, or are reasonably believed to be likely to materially affect, HTALP ’s internal control over financial reporting.


35

Table of Contents

PART II - OTHER INFORMATION
Item 1. Legal Proceedings
We are subject to claims and litigation arising in the ordinary course of business. We do not believe any liability from any reasonably foreseeable disposition of such claims and litigation, individually or in the aggregate, would have a material adverse effect on our accompanying condensed consolidated financial statements.
Item 1A. Risk Factors
There have been no material changes from the risk factors previously disclosed in our 2014 Annual Report on Form 10-K.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Purchases of Equity Securities by the Issuer and Affiliated Purchasers
During the three months ended June 30, 2015 , HTA repurchased shares of its common stock as follows:
Period
 
Total Number of
Shares Purchased (1) (2)
 
Average Price
Paid per Share (1) (2)
 
Total Number of
Shares Purchased
as Part of
Publicly Announced
Plan or Program
 
Maximum Approximate Dollar Value of Shares that May Yet be Purchased Under the Plans or Programs
April 1, 2015 to April 30, 2015
 
—

 
$
—

 
—

 
—

May 1, 2015 to May 31, 2015
 
—

 
—

 
—

 
—

June 1, 2015 to June 30, 2015
 
220

 
24.39

 
—

 
—

 
 
 
 
 
 
 
 
 
(1) Purchases represent shares withheld to satisfy withholding obligations on the vesting of restricted shares. The price paid per share was the then closing price of our common stock on the NYSE.
(2) For each share of common stock redeemed by HTA, HTALP redeems a corresponding number of units in the operating partnership. Therefore, the units in the operating partnership repurchased by HTALP are the same as the shares of common stock repurchased by HTA above.
Item 6. Exhibits
The exhibits listed on the Exhibit Index (following the signatures section of this Quarterly Report on Form 10-Q) are included, and incorporated by reference, in this Quarterly Report on Form 10-Q.


36

Table of Contents

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrants have duly caused this report to be signed on their behalf by the undersigned thereunto duly authorized.
 
Healthcare Trust of America, Inc.
 
 
 
 
By:
/s/ Scott D. Peters
 
Chief Executive Officer, President and Chairman
 
 Scott D. Peters
 
(Principal Executive Officer)
Date:
July 29, 2015
 
 
 
 
 
 
By:
/s/ Robert A. Milligan
 
Chief Financial Officer
 
 Robert A. Milligan
 
(Principal Financial Officer and Principal Accounting Officer)
Date:
July 29, 2015
 
 
 
 
 
 

 
Healthcare Trust of America Holdings, LP
 
 
 
 
By:
Healthcare Trust of America, Inc.,
 
its General Partner
 
 
 
 
 
 
By:
/s/ Scott D. Peters
 
Chief Executive Officer, President and Chairman
 
 Scott D. Peters
 
(Principal Executive Officer)
Date:
July 29, 2015
 
 
 
 
 
 
By:
/s/ Robert A. Milligan
 
Chief Financial Officer
 
 Robert A. Milligan
 
(Principal Financial Officer and Principal Accounting Officer)
Date:
July 29, 2015
 
 



37

Table of Contents

EXHIBIT INDEX
The following exhibits are included, or incorporated by reference, in this Quarterly Report on Form 10-Q for the quarter ended June 30, 2015 (and are numbered in accordance with Item 601 of Regulation S-K).
10.1*†
Healthcare Trust of America, Inc. 2006 Independent Directors Compensation Plan, effective as of July 8, 2015.
10.2*
Form of Indemnification Agreement executed by Steve W. Patterson and Peter N. Foss.
31.1*
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.2*
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
31.3*
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
31.4*
Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.1**
Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Inc.
32.2**
Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America, Inc.
32.3**
Certification of Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
32.4**
Certification of Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as created by Section 906 of the Sarbanes-Oxley Act of 2002 for Healthcare Trust of America Holdings, LP.
101.INS*
XBRL Instance Document.
101.SCH*
XBRL Taxonomy Extension Schema Document.
101.CAL*
XBRL Taxonomy Extension Calculation Linkbase Document.
101.DEF*
XBRL Taxonomy Extension Definition Linkbase Document.
101.LAB*
XBRL Taxonomy Extension Label Linkbase Document.
101.PRE*
XBRL Taxonomy Extension Presentation Linkbase Document.
 
 
*
Filed herewith.
**
Furnished herewith.
†
Compensatory plan or arrangement.




38

Exhibit 10.1

HEALTHCARE TRUST OF AMERICA, INC.
2006 INDEPENDENT DIRECTORS COMPENSATION PLAN
(Effective Date: July 8, 2015)
ARTICLE 1
PURPOSE
1.1.      PURPOSE . The purpose of the Healthcare Trust of America, Inc. 2006 Independent Directors Compensation Plan is to attract, retain and compensate highly-qualified individuals who are not employees of Healthcare Trust of America, Inc. or any of its Affiliates for service as members of the Board by providing them with competitive compensation and an ownership interest in the Stock of the Company. The Company intends that the Plan will benefit the Company and its stockholders by allowing Independent Directors to have a personal financial stake in the Company through an ownership interest in the Stock and will closely associate the interests of Independent Directors with that of the Company’s stockholders.
1.2.      ELIGIBILITY . Independent Directors of the Company who are Eligible Participants, as defined below, shall automatically be participants in the Plan.
1.3.      EFFECTIVE DATE . This version of the Plan is effective as of the Effective Date. For compensation awarded or earned prior to such date, see the version of the Plan in effect on the relevant date.
ARTICLE 2
DEFINITIONS
2.1.     DEFINITIONS . Unless the context clearly indicates otherwise, the following terms shall have the following meanings:
“ AFFILIATE ” has the meaning given such term in the Equity Incentive Plan.
“ BASE RETAINER ” means the retainer (excluding meeting fees and expenses) payable by the Company to an Independent Director pursuant to Section 5.1 hereof for service as a director of the Company, as such amount may be changed from time to time.
“ BOARD ” means the Board of Directors of the Company.
“CHANGE IN CONTROL” has the meaning given such term in the Equity Incentive Plan.

“ CHARTER ” means the articles of incorporation of the Company, as such articles of incorporation may be amended from time to time.
“ CODE ” means the Internal Revenue Code of 1986, as amended.
“ COMMITTEE ” has the meaning given such term in the Equity Incentive Plan.
“ COMPANY ” means Healthcare Trust of America, Inc., a Maryland corporation.
“ DIRECTOR DISABILITY ” means any illness or other physical or mental condition of an Independent Director that renders him or her incapable of performing as a director of the Company, or any medically determinable illness or other physical or mental condition resulting from a bodily injury, disease or mental disorder which, in the judgment of the Board, is permanent and continuous in nature.



Notwithstanding the foregoing, Disability shall have the same meaning as set forth in any regulations, revenue procedure or revenue rulings issued by the Secretary of the United States Treasury applicable to Section 409A(d) of the Code. The Board may require such medical or other evidence as it deems necessary to judge the nature and permanency of an Independent Director’s condition.
“ EFFECTIVE DATE ” means the “Effective Date” set forth above.
“ ELIGIBLE PARTICIPANT ” means any person who is an Independent Director on the Effective Date set forth above or becomes an Independent Director while this Plan is in effect; except that during any period a director is prohibited from participating in the Plan by his or her employer or otherwise waives participation in the Plan, such director shall not be an Eligible Participant.
“ EQUITY INCENTIVE PLAN ” means the Healthcare Trust of America, Inc. 2006 Incentive Plan, or any subsequent equity compensation plan approved by the Company’s stockholders and designated as the Equity Incentive Plan for purposes of this Plan.
“ FAIR MARKET VALUE ” has the meaning given such term in the Equity Incentive Plan.

“ INDEPENDENT DIRECTOR ” has the meaning given such term in the Equity Incentive Plan.
“ PLAN ” means this Healthcare Trust of America, Inc. 2006 Independent Directors Compensation Plan, as amended from time to time.
“ PLAN YEAR ” means the approximate 12-month period beginning with the annual stockholders meeting and ending at the next annual stockholders meeting.
“ RETIREMENT ” means a termination of an Independent Director’s service as a member of the Board as a result of the Independent Director’s term as a member of the Board expiring and the Independent Director does not stand for re-election as a member of the Board (or the Independent Director is re-nominated but not re-elected for a new term on the Board); provided, however, that such a termination will not constitute a Retirement for purposes hereof unless (a) the Independent Director has served on the Board for not less than four (4) full years as of the date of such termination, and (b) the Independent Director’s service on the Board continues through the day before the date of the annual meeting of stockholders at which the Independent Director’s term as a member of the Board is scheduled to expire.
“ SHARES ” has the meaning given such term in the Equity Incentive Plan.
“ STOCK ” has the meaning given such term in the Equity Incentive Plan.
“SUPPLEMENTAL ANNUAL RETAINER” means the annual cash retainer (excluding meeting fees and expenses) payable by the Company to an Independent Director pursuant to Section 5.2 hereof for service as the Lead Independent Director of the Board or the chair of a committee of the Board, as such amount may be changed from time to time.



2



ARTICLE 3
ADMINISTRATION
3.1.      ADMINISTRATION . The Plan shall be administered by the Board. Subject to the provisions of the Plan, the Board shall be authorized to interpret the Plan, to establish, amend and rescind any rules and regulations relating to the Plan, and to make all other determinations necessary or advisable for the administration of the Plan. The Board’s interpretation of the Plan, and all actions taken and determinations made by the Board pursuant to the powers vested in it hereunder, shall be conclusive and binding upon all parties concerned including the Company, its stockholders and persons granted awards under the Plan. The Board may appoint a plan administrator to carry out the ministerial functions of the Plan, but the administrator shall have no other authority or powers of the Board.
3.2.      RELIANCE . In administering the Plan, the Board may rely upon any information furnished by the Company, its public accountants and other experts. No individual will have personal liability by reason of anything done or omitted to be done by the Company or the Board in connection with the Plan. This limitation of liability shall not be exclusive of any other limitation of liability to which any such person may be entitled under the Company’s certificate of incorporation or otherwise.
3.3.      INDEMNIFICATION . Each person who is or has been a member of the Board or who otherwise participates in the administration or operation of this Plan shall be indemnified by the Company against, and held harmless from, any loss, cost, liability or expense that may be imposed upon or incurred by him or her in connection with or resulting from any claim, action, suit or proceeding in which such person may be involved by reason of any action taken or failure to act under the Plan and shall be fully reimbursed by the Company for any and all amounts paid by such person in satisfaction of judgment against him or her in any such action, suit or proceeding, provided he or she will give the Company an opportunity, by written notice to the Board, to defend the same at the Company’s own expense before he or she undertakes to defend it on his or her own behalf. This right of indemnification shall not be exclusive of any other rights of indemnification to which any such person may be entitled under the Company’s Charter, Bylaws, contract or Delaware law.
ARTICLE 4
SHARES
4.1.    SOURCE OF SHARES FOR THE PLAN . The shares of Restricted Stock or other equity awards that may be issued pursuant to the Plan shall be issued under the Equity Incentive Plan, subject to all of the terms and conditions of the Equity Incentive Plan. The terms contained in the Equity Incentive Plan are incorporated into and made a part of this Plan with respect to shares of Restricted Stock or other equity awards granted pursuant hereto and any such awards shall be governed by and construed in accordance with the Equity Incentive Plan. In the event of any actual or alleged conflict between the provisions of the Equity Incentive Plan and the provisions of this Plan, the provisions of the Equity Incentive Plan shall be controlling and determinative. This Plan does not constitute a separate source of shares for the grant of the equity awards described herein.



3



ARTICLE 5
BASE RETAINER, MEETING FEES AND EXPENSES
5.1.      BASE RETAINER . Each Eligible Participant shall be paid a Base Retainer for service as a director during each Plan Year. The amount of the Base Retainer shall be established from time to time by the Board. Until changed by the Board, the Base Retainer for a full Plan Year shall be $50,000. The Base Annual Retainer shall be payable in approximately equal quarterly installments in advance, beginning on the date of the annual stockholders meeting.
Each person who first becomes an Eligible Participant on a date other than the beginning of a Plan Year shall be paid a retainer equal to the quarterly installment of the Base Annual Retainer for the first quarter of eligibility, prorated based on the number of full months he or she serves as an Independent Director during such quarter. Payment of such prorated Base Annual Retainer shall begin on the date that the person first becomes an Eligible Participant.
5.2.      SUPPLEMENTAL ANNUAL RETAINERS . An Independent Director who serves as Lead Independent Director of the Board shall be paid a Supplemental Annual Retainer for such service during a Plan Year, payable at the same times as installments of the Base Retainer are paid. Until changed by the Board, the Supplemental Annual Retainer for the Lead Independent Director shall be $35,000. The chairperson of a committee of the Board shall be paid a Supplemental Annual Retainer for his or her service as such chairperson during a Plan Year, payable at the same times as installments of the Base Retainer are paid. The amount of the Supplemental Annual Retainer for the chairperson of a committee of the Board shall be established from time to time by the Board. Until changed by the Board, (a) the Supplemental Annual Retainer for a full Plan Year for the chairperson of a committee of the Board (other than the Audit Committee) shall be $12,500, and (b) the Supplemental Annual Retainer for a full Plan Year for the chairperson of the Audit Committee shall be $15,000. A pro rata Supplemental Annual Retainer will be paid to any Eligible Participant who becomes the Lead Independent Director or the chairperson of a committee of the Board on a date other than the beginning of a Plan Year, based on the number of full months he or she serves in such position.
5.3.      MEETING FEES . An Independent Director shall not be entitled to any meeting fee for any of the first four meetings of the Board he or she attends in each Plan Year or for any of the first four meetings of Board committees he or she attends in each Plan Year. To the extent an Independent Director attends more than four Board meetings in a Plan Year, the director will be entitled to a meeting fee of $1,500 for each such meeting attended.
5.4.     An Independent Director shall also not be entitled any meeting fee for any of the first four meetings of a Board committee on which a Director serves. To the extent an Independent Director attends more than four meetings of their respective Board committees in a Plan Year, the director will be entitled to a meeting fee of $1,500 for each such meeting attended. (For example, if, during a particular Plan Year, an Independent Director attended four meetings of one Board committee and three meetings of a second Board committee, the director would not be entitled to any meeting fees. However, if an Independent Director attended four meetings of one Board committee and six meetings of a second Board committee, the director would be entitled to aggregate meeting fees of $3,000 for that Plan Year.) The amount of such per- meeting fee is subject to change from time to time by the Board. If an Independent Director attends a meeting of the

4



Board and a meeting of a committee (in each case, whether non- telephonic or telephonic) on a single day, he or she shall be credited with attending both the Board and the committee meeting for purposes of this Section 5.3.
5.5.      TRAVEL EXPENSE REIMBURSEMENT . All Independent Directors shall be reimbursed for reasonable travel expenses (including spouse’s expenses to attend events to which spouses are invited) in connection with attendance at meetings of the Board and its committees, or other Company functions at which the Chair of the Board or the Chief Executive Officer requests the Independent Director to participate.
ARTICLE 6
EQUITY COMPENSATION
6.1.      INITIAL RESTRICTED STOCK GRANT . On the first date an Independent Director is initially elected or appointed to the Board on or following the Effective Date (and other than in connection with an annual meeting of the Company’s stockholders), such director shall receive an award of Restricted Stock with respect to a number of Shares determined by multiplying (a) the quotient obtained by dividing $100,000 by the Fair Market Value of a Share on the date of grant of such award, by (b) a fraction, the numerator of which shall be the number of days remaining in the 365-day period following the most recent annual meeting of the Company’s stockholders that occurred prior to the date of such director’s initial election or appointment, and the denominator of which shall be 365 (but in no event shall such fraction be greater than one), such number to be rounded to the nearest whole number of Shares. Such shares of Restricted Stock shall be subject to the terms and restrictions described below in this Article 6, shall be in addition to any otherwise applicable annual grant of Restricted Stock granted to such Independent Director under Section 6.2, and shall be subject to share availability under the Equity Incentive Plan.
6.2.      SUBSEQUENT RESTRICTED STOCK GRANT . Subject to share availability under the Equity Incentive Plan, upon subsequent re-election of the Independent Director to the Board at an annual meeting of the Company’s stockholders on or following the Effective Date, such director shall receive an award of Restricted Stock with respect to a number of Shares determined by dividing (a) $100,000 by (b) the Fair Market Value of a Share on the date of grant of such award, such number to be rounded to the nearest whole number of Shares.
6.3.      TERMS AND CONDITIONS OF RESTRICTED STOCK . Shares of Restricted Stock granted under this Article 6 shall be evidenced by a written Award Certificate, and shall be subject to the terms and conditions described below and of the Equity Incentive Plan.
(i)     Restrictions . The shares of Stock granted pursuant to Article 6 are subject to each of the following restrictions. “Restricted Stock” mean those shares that are subject to the restrictions imposed hereunder which restrictions have not then expired or terminated. Restricted Stock may not be sold, transferred, exchanged, assigned, pledged, hypothecated or otherwise encumbered to or in favor of any party other than the Company, or be subjected to any lien, obligation or liability of the grantee to any other party other than the Company. If the grantee’s service as a director of the Company terminates prior to the Vesting Date (as defined in Section 6.3(ii)) other than by reason of his or her death or Disability or his or her Retirement, then the grantee shall forfeit all of his or

5



her right, title and interest in and to any unvested shares of Restricted Stock as of the date of such termination from the Board and such unvested shares of Restricted Stock shall be reconveyed to the Company immediately following the event of forfeiture, without further consideration or any act or action by the grantee. The restrictions imposed under this Section 6.3(i) shall apply to all shares of Stock or other securities issued with respect to shares of Restricted Stock hereunder in connection with any merger, reorganization, consolidation, recapitalization, stock dividend or other change in corporate structure affecting the Stock.
(ii)     Vesting . The shares of Restricted Stock shall vest and become non-forfeitable as to twenty percent (20%) of the shares on the Grant Date and as to twenty percent (20%) on each of the first four anniversaries of the Grant Date; provided, however, that the shares of Restricted Stock shall become fully vested on the earlier occurrence of (i) the termination of the grantee’s service as a director of the Company due to his or her death or Disability, (ii) the termination of the grantee’s service as a director of the Company due to his or her Retirement, or (iii) a Change in Control of the Company (in any such case, the “Vesting Date”). If the grantee’s service as a director of the Company terminates other than as described in clause (i), (ii) or (iii) of the foregoing sentence, then the grantee shall forfeit all of his or her right, title and interest in and to any unvested shares of Restricted Stock as of the date of such termination from the Board and such Restricted Stock shall be reconveyed to the Company without further consideration or any act or action by the grantee.
(iii)     Delivery of Shares . The shares of Restricted Stock granted under Article 6 will be registered in the name of grantee as of the Grant Date and will be held by the Company during the Restricted Period in certificated or uncertificated form. If a certificate for Restricted Stock is issued during the Restricted Period with respect to such shares, such certificate shall be registered in the name of the grantee and shall bear a legend in substantially the following form (in addition to any legend required under applicable state securities laws):
“This certificate and the shares of stock represented hereby are subject to the terms and conditions (including forfeiture and restrictions against transfer) contained in a Restricted Stock Certificate between the registered owner of the shares represented hereby and Healthcare Trust of America, Inc. Release from such terms and conditions shall be made only in accordance with the provisions of such Agreement, copies of which are on file in the offices of Healthcare Trust of America, Inc.”
Stock certificates for the shares, without the first above legend, shall be delivered to the Independent Director or his or her designee upon request after the expiration of the Restricted Period, but delivery may be postponed for such period as may be required for the Company with reasonable diligence to comply if deemed advisable by the Company, with registration requirements under the Securities Act of 1933, as amended, listing requirements under the rules of any stock exchange, and requirements under any other law or regulation applicable to the issuance or transfer of the shares.
(iv)     Rights as a Stockholder . An Independent Director shall have all the rights of a stockholder of the Company with respect to the Restricted Stock, including voting rights and the right to receive dividends and other distributions paid with respect to such shares. If any such dividend

6



or distribution is paid in shares of Stock, such shares shall be subject to the same restrictions on transferability and risks of forfeiture during the Restricted Period as the shares of Restricted Stock with respect to which they were paid.
ARTICLE 7
AMENDMENT, MODIFICATION AND TERMINATION
7.1.     AMENDMENT, MODIFICATION AND TERMINATION . The Board may terminate or suspend the Plan at any time, without stockholder approval. The Board may amend the Plan at any time and for any reason without stockholder approval; provided, however, that the Board may condition any amendment on the approval of stockholders of the Company if such approval is necessary or deemed advisable with respect to tax, securities or other applicable laws, policies or regulations. No termination, modification or amendment of the Plan may, without the consent of an Independent Director, adversely affect an Independent Director’s rights under an award granted prior thereto.
ARTICLE 8
GENERAL PROVISIONS
8.1.      ADJUSTMENTS . The adjustment provisions of the Equity Incentive Plan shall apply with respect to equity awards outstanding or to be granted pursuant to this Plan.
8.2.      DURATION OF THE PLAN . The Plan shall remain in effect until terminated by the Board.
8.3.      EXPENSES OF THE PLAN . The expenses of administering the Plan shall be borne by the Company.
8.4.      STATUS OF THE PLAN . The Plan is intended to be a nonqualified, unfunded plan of deferred compensation under the Code. Plan benefits shall be paid from the general assets of the Company or as otherwise directed by the Company. A participant shall have the status of a general unsecured creditor of the Company with respect to his or her right to receive Stock or other payment under the Plan. No right or interest in such payment shall be subject to the claims of creditors of the Independent Director or to liability for the debts, contracts or engagements of the Independent Director, or shall be subject to disposition by transfer, alienation, anticipation, pledge, encumbrance, assignment or any other means whether such disposition be voluntary or involuntary or by operation of law by judgment, levy, attachment, garnishment or any other legal or equitable proceedings (including bankruptcy), and any attempted disposition thereof shall be null and void and of no effect; provided, however, that nothing in this Plan shall prevent transfers by will or by the applicable laws of descent and distribution. To the extent that any participant acquires the right to receive payments under the Plan (from whatever source), such right shall be no greater than that of an unsecured general creditor of the Company. Participants and their beneficiaries shall not have any preference or security interest in the assets of the Company other than as a general unsecured creditor.

7


Exhibit 10.2

INDEMNIFICATION AGREEMENT
THIS INDEMNIFICATION AGREEMENT is made and entered into this        day of __________, 2015 (“Agreement”), by and between Healthcare Trust of America, Inc., a Maryland corporation (the “Company”), and __________________ (“Indemnitee”).
WHEREAS, at the request of the Company, Indemnitee currently serves as a director or officer of the Company and may, therefore, be subjected to claims, suits or proceedings arising as a result of his or her service; and
WHEREAS, as an inducement to Indemnitee to continue to serve as such director or officer, the Company has agreed to indemnify and to advance expenses and costs incurred by Indemnitee in connection with any such claims, suits or proceedings, subject to certain limitations set forth herein; and
WHEREAS, the parties by this Agreement desire to set forth their agreement regarding indemnification and advance of expenses;
NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:
Section 1.  Definitions . For purposes of this Agreement:
(a) “Change in Control” means a change in control of the Company occurring after the Effective Date of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or in response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended (the “Act”), whether or not the Company is then subject to such reporting requirement; provided, however, that, without limitation, such a Change in Control shall be deemed to have occurred if after the Effective Date (i) any “person” (as such term is used in Sections 13(d) and 14(d) of the Act) is or becomes the “beneficial owner” (as defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 15% or more of the combined voting power of all of the Company’s then outstanding securities entitled to vote generally in the election of directors without the prior approval of at least two-thirds of the members of the Board of Directors in office immediately prior to such person’s attaining such percentage interest; (ii) the Company is a party to a merger, consolidation, sale of assets, plan of liquidation or other reorganization not approved by at least two-thirds of the members of the Board of Directors then in office, as a consequence of which members of the Board of Directors in office immediately prior to such transaction or event constitute less than a majority of the Board of Directors thereafter; or (iii) at any time, a majority of the members of the Board of Directors are not individuals (A) who were directors as of the Effective Date or (B) whose election by the Board of Directors or nomination for election by the Company’s stockholders was approved by the affirmative vote of at least two-thirds of the directors then in office who were directors as of the Effective Date or whose election for nomination for election was previously so approved.

1


(b) “Corporate Status” means the status of a person as a present or former director, officer, employee or agent of the Company or as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any other foreign or domestic corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise that such person is or was serving in such capacity at the request of the Company. As a clarification and without limiting the circumstances in which Indemnitee may be serving at the request of the Company, service by Indemnitee shall be deemed to be at the request of the Company if Indemnitee serves or served as a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise (i) of which a majority of the voting power or equity interest is owned directly or indirectly by the Company or (ii) the management of which is controlled directly or indirectly by the Company.
(c) “Disinterested Director” means a director of the Company who is not and was not a party to the Proceeding in respect of which indemnification and/or advance of Expenses is sought by Indemnitee.
(d) “Effective Date” means the date of this Agreement.
(e) “Expenses” means any and all reasonable and out-of-pocket attorneys’ fees and costs, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, federal, state, local or foreign taxes imposed on Indemnitee as a result of the actual or deemed receipt of any payments under this Agreement, ERISA excise taxes and penalties and any other disbursements or expenses incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in or otherwise participating in a Proceeding. Expenses shall also include Expenses incurred in connection with any appeal resulting from any Proceeding including, without limitation, the premium for, security for and other costs relating to any cost bond supersedeas bond or other appeal bond or its equivalent.
(f) “Independent Counsel” means a law firm, or a member of a law firm, that is experienced in matters of corporation law and neither is, nor in the past five years has been, retained to represent: (i) the Company or Indemnitee in any matter material to either such party (other than with respect to matters concerning Indemnitee under this Agreement or of other indemnitees under similar indemnification agreements), or (ii) any other party to or participant or witness in the Proceeding giving rise to a claim for indemnification or advance of Expenses hereunder. Notwithstanding the foregoing, the term “Independent Counsel” shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee’s rights under this Agreement.
(g) “Proceeding” means any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other proceeding, whether brought by or in the right of the Company or otherwise and whether of a civil (including intentional or unintentional tort claims), criminal, administrative or investigative (formal or informal) nature, including any appeal therefrom, except one pending or

2


completed on or before the Effective Date, unless otherwise specifically agreed in writing by the Company and Indemnitee. If Indemnitee reasonably believes that a given situation may lead to or culminate in the institution of a Proceeding, such situation shall also be considered a Proceeding.
Section 2.  Services by Indemnitee . Indemnitee will serve as a director or officer of the Company. However, this Agreement shall not impose any independent obligation on Indemnitee or the Company to continue Indemnitee’s service to the Company. This Agreement shall not be deemed an employment contract between the Company (or any other entity) and Indemnitee.
Section 3.  Indemnification — General . Subject to the limitations in Section 7, the Company shall indemnify, and advance Expenses to, Indemnitee (a) as provided in this Agreement and (b) as otherwise permitted by Maryland law in effect on the Effective Date and as amended from time to time; provided, however, that no change in Maryland law shall have the effect of reducing the benefits available to Indemnitee hereunder based on Maryland law as in effect on the Effective Date. Subject to the limitations in Section 7, the rights of Indemnitee provided in this Section 3 shall include, without limitation, the rights set forth in the other sections of this Agreement, including any additional indemnification permitted by Section 2-418(g) of the Maryland General Corporation Law (the “MGCL”).
Section 4.  Rights to Indemnification . Subject to the limitations in Section 7, if, by reason of Indemnitee’s Corporate Status, Indemnitee is, or is threatened to be, made a party to any Proceeding, the Company shall indemnify Indemnitee against all judgments, penalties, fines and amounts paid in settlement and all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection with any such Proceeding unless it is established by clear and convincing evidence that (i) the act or omission of Indemnitee was material to the matter giving rise to the Proceeding and (a) was committed in bad faith or (b) was the result of active and deliberate dishonesty, (ii) Indemnitee actually received an improper personal benefit in money, property or services or (iii) in the case of any criminal Proceeding, Indemnitee had reasonable cause to believe that his or her conduct was unlawful.
Section 5.  Court-Ordered Indemnification . Subject to the limitations in Section 7(a) and (b), a court of appropriate jurisdiction, upon application of Indemnitee and such notice as the court shall require, may order indemnification of Indemnitee in the following circumstances:
(a) if such court determines that Indemnitee is entitled to reimbursement under Section 2-418(d)(1) of the MGCL, the court shall order indemnification, in which case Indemnitee shall be entitled to recover the Expenses of securing such reimbursement; or
(b) if such court determines that Indemnitee is fairly and reasonably entitled to indemnification in view of all the relevant circumstances, whether or not Indemnitee (i) has met the standards of conduct set forth in Section 2-418(b) of the MGCL or (ii) has been adjudged liable for receipt of an improper personal benefit under Section 2-418(c) of the MGCL, the court may order such indemnification as the court shall deem proper. However, indemnification with respect to any Proceeding by or in the right of the Company or in which liability shall have been adjudged in the circumstances described in Section 2-418(c) of the MGCL shall be limited to Expenses.

3


Section 6.  Indemnification for Expenses of an Indemnitee Who is Wholly or Partly Successful . Subject to the limitations in Section 7, to the extent that Indemnitee was or is, by reason of his or her Corporate Status, made a party to (or otherwise becomes a participant in) any Proceeding and is successful, on the merits or otherwise, in the defense of such Proceeding, he or she shall be indemnified for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee under this Section 6 for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each such claim, issue or matter, allocated on a reasonable and proportionate basis. For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.
Section 7.  Limitations on Indemnification . Notwithstanding any other provision of this Agreement (other than Section 5), Indemnitee shall not be entitled to:
(a) indemnification hereunder if the Proceeding was one by or in the right of the Company and Indemnitee is adjudged to be liable to the Company;
(b) indemnification hereunder if Indemnitee is adjudged to be liable on the basis that personal benefit was improperly received in any Proceeding charging improper personal benefit to Indemnitee, whether or not involving action in the Indemnitee’s Corporate Status; or
(c) indemnification or advance of Expenses hereunder if the Proceeding was brought by Indemnitee, unless: (i) the Proceeding was brought to enforce indemnification under this Agreement, and then only to the extent in accordance with and as authorized by Section 12 of this Agreement, or (ii) the Company’s charter or Bylaws, a resolution of the stockholders entitled to vote generally in the election of directors or of the Board of Directors or an agreement approved by the Board of Directors to which the Company is a party expressly provide otherwise.
Section 8.  Advance of Expenses for an Indemnitee . If, by reason of Indemnitee’s Corporate Status, Indemnitee is, or is threatened to be, made a party to any Proceeding, the Company shall, without requiring a preliminary determination of Indemnitee’s ultimate entitlement to indemnification hereunder and except as set forth in the following sentence, advance all reasonable Expenses incurred by or on behalf of Indemnitee in connection with such Proceeding within ten days after the receipt by the Company of a statement or statements requesting such advance or advances from time to time, whether prior to or after final disposition of such Proceeding. The statement or statements requesting advance or advances shall reasonably evidence the Expenses incurred by Indemnitee and shall include or be preceded or accompanied by a written affirmation by Indemnitee of Indemnitee’s good faith belief that the standard of conduct necessary for indemnification by the Company as authorized by law and by this Agreement has been met and a written undertaking by or on behalf of Indemnitee, in substantially the form attached hereto as  Exhibit A  or in such form as may be required under applicable law as in effect at the time of the execution thereof, to reimburse the portion of any

4


Expenses advanced to Indemnitee relating to claims, issues or matters in the Proceeding as to which it shall ultimately be established, by clear and convincing evidence, that the standard of conduct has not been met by Indemnitee and which have not been successfully resolved as described in Section 6 of this Agreement. To the extent that Expenses advanced to Indemnitee do not relate to a specific claim, issue or matter in the Proceeding, such Expenses shall be allocated on a reasonable and proportionate basis. The undertaking required by this Section 8 shall be an unlimited general obligation by or on behalf of Indemnitee and shall be accepted without reference to Indemnitee’s financial ability to repay such advanced Expenses and without any requirement to post security therefor.
Section 9.  Indemnification and Advance of Expenses as a Witness or Other Participant . Subject to the limitations in Section 7, to the extent that Indemnitee is or may be, by reason of Indemnitee’s Corporate Status, made a witness or otherwise asked to participate in any Proceeding, whether instituted by the Company or any other party, and to which Indemnitee is not a party, Indemnitee shall be advanced all reasonable Expenses and indemnified against all Expenses actually and reasonably incurred by Indemnitee or on Indemnitee’s behalf in connection therewith within ten days after the receipt by the Company of a statement or statements requesting any such advance or indemnification from time to time, whether prior to or after final disposition of such Proceeding. Such statement or statements shall reasonably evidence the Expenses incurred by Indemnitee.
Section 10.  Procedure for Determination of Entitlement to Indemnification .
(a) To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request, including therein or therewith such documentation and information as is reasonably available to Indemnitee and is reasonably necessary to determine whether and to what extent Indemnitee is entitled to indemnification. Indemnitee may submit one or more such requests from time to time and at such time(s) as Indemnitee deems appropriate in Indemnitee’s sole discretion. The officer of the Company receiving any such request from Indemnitee shall, promptly upon receipt of such a request for indemnification, advise the Board of Directors in writing that Indemnitee has requested indemnification.
(b) Upon written request by Indemnitee for indemnification pursuant to Section 10(a) above, a determination, if required by applicable law, with respect to Indemnitee’s entitlement thereto shall promptly be made in the specific case: (i) if a Change in Control shall have occurred, by Independent Counsel, in a written opinion to the Board of Directors, a copy of which shall be delivered to Indemnitee, which Independent Counsel shall be selected by Indemnitee and approved by the Board of Directors in accordance with Section 2-418(e)(2)(ii) of the MGCL, which approval shall not be unreasonably withheld; or (ii) if a Change in Control shall not have occurred, (A) by the Board of Directors by a majority vote of a quorum consisting of Disinterested Directors or, if such a quorum cannot be obtained, then by a majority vote of a duly authorized committee of the Board of Directors consisting solely of one or more Disinterested Directors, (B) if Independent Counsel has been selected by the Board of Directors in accordance with Section 2-418(e)(2)(ii) of the MGCL and approved by Indemnitee, which approval shall not be unreasonably withheld, by Independent Counsel, in a written opinion to the

5


Board of Directors, a copy of which shall be delivered to Indemnitee or (C) if so directed by a majority of the members of the Board of Directors, by the stockholders of the Company. If it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten days after such determination. Indemnitee shall cooperate with the person, persons or entity making such determination with respect to Indemnitee’s entitlement to indemnification, including providing to such person, persons or entity upon reasonable advance request any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination in the discretion of the Board of Directors or Independent Counsel if retained pursuant to clause (ii)(B) of this Section 10(b). Any Expenses incurred by Indemnitee in so cooperating with the person, persons or entity making such determination shall be borne by the Company (irrespective of the determination as to Indemnitee’s entitlement to indemnification) and the Company shall indemnify and hold Indemnitee harmless therefrom.
(c) The Company shall pay the reasonable fees and expenses of Independent Counsel, if one is appointed.
Section 11.  Presumptions and Effect of Certain Proceedings .
(a) In making any determination with respect to entitlement to indemnification hereunder, the person or persons or entity making such determination shall presume that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making of any determination contrary to that presumption.
(b) The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, upon a plea of  nolo   contendere  or its equivalent, or entry of an order of probation prior to judgment, does not create a presumption that Indemnitee did not meet the requisite standard of conduct described herein for indemnification.
(c) The knowledge and/or actions, or failure to act, of any other director, officer, employee or agent of the Company or any other director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any other foreign or domestic corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise shall not be imputed to Indemnitee for purposes of determining any other right to indemnification under this Agreement.
Section 12.  Remedies of Indemnitee .
(a) If (i) a determination is made pursuant to Section 10(b) of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advance of Expenses is not timely made pursuant to Section 8 or 9 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(b) of this Agreement within 60 days after receipt by the Company of the request for indemnification, (iv) payment of indemnification is not made pursuant to Section 6 or 9 of this Agreement within ten days after

6


receipt by the Company of a written request therefor, or (v) payment of indemnification pursuant to any other section of this Agreement or the charter or Bylaws of the Company is not made within ten days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication in an appropriate court located in the State of Maryland, or in any other court of competent jurisdiction, of his or her entitlement to such indemnification or advance of Expenses. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence a proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); provided, however, that the foregoing clause shall not apply to a proceeding brought by Indemnitee to enforce his or her rights under Section 6 of this Agreement. Except as set forth herein, the provisions of Maryland law (without regard to its conflicts of laws rules) shall apply to any such arbitration. The Company shall not oppose Indemnitee’s right to seek any such adjudication or award in arbitration.
(b) In any judicial proceeding or arbitration commenced pursuant to this Section 12, Indemnitee shall be presumed to be entitled to indemnification or advance of Expenses, as the case may be, under this Agreement and the Company shall have the burden of proving that Indemnitee is not entitled to indemnification or advance of Expenses, as the case may be. If Indemnitee commences a judicial proceeding or arbitration pursuant to this Section 12, Indemnitee shall not be required to reimburse the Company for any advances pursuant to Section 8 of this Agreement until a final determination is made with respect to Indemnitee’s entitlement to indemnification (as to which all rights of appeal have been exhausted or lapsed). The Company shall, to the fullest extent not prohibited by law, be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all of the provisions of this Agreement.
(c) If a determination shall have been made pursuant to Section 10(b) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee’s statement not materially misleading, in connection with the request for indemnification.
(d) In the event that Indemnitee is successful in seeking, pursuant to this Section 12, a judicial adjudication of or an award in arbitration to enforce his or her rights under, or to recover damages for breach of, this Agreement, Indemnitee shall be entitled to recover from the Company, and shall be indemnified by the Company for, any and all Expenses actually and reasonably incurred by him or her in such judicial adjudication or arbitration. If it shall be determined in such judicial adjudication or arbitration that Indemnitee is entitled to receive part but not all of the indemnification or advance of Expenses sought, the Expenses incurred by

7


Indemnitee in connection with such judicial adjudication or arbitration shall be appropriately prorated.
(e) Interest shall be paid by the Company to Indemnitee at the maximum rate allowed to be charged for judgments under the Courts and Judicial Proceedings Article of the Annotated Code of Maryland for amounts which the Company pays or is obligated to pay for the period (i) commencing with either the tenth day after the date on which the Company was requested to advance Expenses in accordance with Section 8 or 9 of this Agreement or the 60 th  day after the date on which the Company was requested to make the determination of entitlement to indemnification under Section 10(b) of this Agreement, as applicable, and (ii) ending on the date such payment is made to Indemnitee by the Company.
Section 13.  Defense of the Underlying Proceeding .
(a) Indemnitee shall notify the Company promptly in writing upon being served with any summons, citation, subpoena, complaint, indictment, request or other document relating to any Proceeding which may result in the right to indemnification or the advance of Expenses hereunder and shall include with such notice a description of the nature of the Proceeding and a summary of the facts underlying the Proceeding. The failure to give any such notice shall not disqualify Indemnitee from the right, or otherwise affect in any manner any right of Indemnitee, to indemnification or the advance of Expenses under this Agreement unless the Company’s ability to defend in such Proceeding or to obtain proceeds under any insurance policy is materially and adversely prejudiced thereby, and then only to the extent the Company is thereby actually so prejudiced.
(b) Subject to the provisions of the last sentence of this Section 13(b) and of Section 13(c) below, the Company shall have the right to defend Indemnitee in any Proceeding which may give rise to indemnification hereunder; provided, however, that the Company shall notify Indemnitee of any such decision to defend within 15 calendar days following receipt of notice of any such Proceeding under Section 13(a) above. The Company shall not, without the prior written consent of Indemnitee, which shall not be unreasonably withheld or delayed, consent to the entry of any judgment against Indemnitee or enter into any settlement or compromise which (i) includes an admission of fault of Indemnitee, (ii) does not include, as an unconditional term thereof, the full release of Indemnitee from all liability in respect of such Proceeding, which release shall be in form and substance reasonably satisfactory to Indemnitee or (iii) would impose any Expense, judgment, fine, penalty or limitation on Indemnitee. This Section 13(b) shall not apply to a Proceeding brought by Indemnitee under Section 12 above.
(c) Notwithstanding the provisions of Section 13(b) above, if in a Proceeding to which Indemnitee is a party by reason of Indemnitee’s Corporate Status, (i) Indemnitee reasonably concludes, based upon an opinion of counsel approved by the Company, which approval shall not be unreasonably withheld, that he or she may have separate defenses or counterclaims to assert with respect to any issue which may not be consistent with other defendants in such Proceeding, (ii) Indemnitee reasonably concludes, based upon an opinion of counsel approved by the Company, which approval shall not be unreasonably withheld, that an actual or apparent conflict of interest or potential conflict of interest exists between Indemnitee and the Company,

8


or (iii) if the Company fails to assume the defense of such Proceeding in a timely manner, Indemnitee shall be entitled to be represented by separate legal counsel of Indemnitee’s choice, subject to the prior approval of the Company, which approval shall not be unreasonably withheld, at the expense of the Company. In addition, if the Company fails to comply with any of its obligations under this Agreement or in the event that the Company or any other person takes any action to declare this Agreement void or unenforceable, or institutes any Proceeding to deny or to recover from Indemnitee the benefits intended to be provided to Indemnitee hereunder, Indemnitee shall have the right to retain counsel of Indemnitee’s choice, subject to the prior approval of the Company, which approval shall not be unreasonably withheld, at the expense of the Company (subject to Section 12(d)), to represent Indemnitee in connection with any such matter.
Section 14.  Non-Exclusivity; Survival of Rights; Subrogation; Coordination of Payments .
(a) The rights of indemnification and advance of Expenses as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the charter or Bylaws of the Company, any agreement or a resolution of the stockholders entitled to vote generally in the election of directors or of the Board of Directors, or otherwise. Unless consented to in writing by Indemnitee, no amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal, regardless of whether a claim with respect to such action or inaction is raised prior or subsequent to such amendment, alteration or repeal. No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right or remedy shall be cumulative and in addition to every other right or remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion of any right or remedy hereunder, or otherwise, shall not prohibit the concurrent assertion or employment of any other right or remedy.
(b) In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.
(c) The Company shall not be liable under this Agreement to make any payment of amounts otherwise indemnifiable or payable or reimbursable as Expenses hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement or otherwise.
Section 15.  Insurance . The Company will use its reasonable best efforts to acquire directors and officers liability insurance, on terms and conditions deemed appropriate by the Board of Directors, with the advice of counsel, covering Indemnitee or any claim made against Indemnitee by reason of his or her Corporate Status and covering the Company for any indemnification or advance of Expenses made by the Company to Indemnitee for any claims made against Indemnitee by reason of his or her Corporate Status. Without in any way limiting any other obligation under this Agreement, the Company shall indemnify Indemnitee for any

9


payment by Indemnitee arising out of the amount of any deductible or retention and the amount of any excess of the aggregate of all judgments, penalties, fines, settlements and Expenses incurred by Indemnitee in connection with a Proceeding over the coverage of any insurance referred to in the previous sentence. The purchase, establishment and maintenance of any such insurance shall not in any way limit or affect the rights or obligations of the Company or Indemnitee under this Agreement except as expressly provided herein, and the execution and delivery of this Agreement by the Company and Indemnitee shall not in any way limit or affect the rights or obligations of the Company under any such insurance policies. If, at the time the Company receives notice from any source of a Proceeding to which Indemnitee is a party or a participant (as a witness or otherwise), the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such Proceeding to the insurers in accordance with the procedures set forth in the respective policies.
Section 16.  Reports to Stockholders . To the extent required by the MGCL, the Company shall report in writing to its stockholders the payment of any amounts for indemnification of, or advance of Expenses to, Indemnitee under this Agreement arising out of a Proceeding by or in the right of the Company with the notice of the meeting of stockholders of the Company next following the date of the payment of any such indemnification or advance of Expenses or prior to such meeting.
Section 17.  Duration of Agreement; Binding Effect .
(a) This Agreement shall continue until and terminate ten years after the date that Indemnitee’s Corporate Status shall have ceased; provided, that the rights of Indemnitee hereunder shall continue until the final termination of any Proceeding then pending or threatened in respect of which Indemnitee is granted rights of indemnification or advance of Expenses hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto.
(b) The indemnification and advance of Expenses provided by, or granted pursuant to, this Agreement shall be binding upon and be enforceable by the parties hereto and their respective successors and assigns (including any direct or indirect successor by purchase, merger, consolidation or otherwise to all or substantially all of the business or assets of the Company), shall continue as to an Indemnitee who has ceased to be a director, officer, employee or agent of the Company or a director, trustee, officer, partner, manager, managing member, fiduciary, employee or agent of any other foreign or domestic corporation, partnership, limited liability company, joint venture, trust, employee benefit plan or other enterprise which such person is or was serving in such capacity at the request of the Company, and shall inure to the benefit of Indemnitee and his or her spouse, assigns, heirs, devisees, executors and administrators and other legal representatives.
(c) The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and

10


to the same extent that the Company would be required to perform if no such succession had taken place.
(d) The Company and Indemnitee agree that a monetary remedy for breach of this Agreement, at some later date, may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which Indemnitee may be entitled. Indemnitee shall further be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertakings in connection therewith. The Company acknowledges that, in the absence of a waiver, a bond or undertaking may be required of Indemnitee by a court, and the Company hereby waives any such requirement of such a bond or undertaking.
Section 18.  Severability . If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section, paragraph or sentence of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.
Section 19.  Identical Counterparts . This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. One such counterpart signed by the party against whom enforceability is sought shall be sufficient to evidence the existence of this Agreement.
Section 20.  Headings . The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.
Section 21.  Modification and Waiver . No supplement, modification or amendment of this Agreement shall be binding unless executed in writing by both of the parties hereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions hereof (whether or not similar) nor shall such waiver constitute a continuing waiver.

11


Section 22.  Notices . All notices, requests, demands and other communications hereunder shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, on the day of such delivery, or (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed:
(a) If to Indemnitee, to the address set forth on the signature page hereto.
(b) If to the Company to:
 
Healthcare Trust of America, Inc.
 
Suite 320
 
16435 North Scottsdale Road
 
Scottsdale, Arizona 85254
 
Attn: Chief Executive Officer
 
         
or to such other address as may have been furnished in writing to Indemnitee by the Company or to the Company by Indemnitee, as the case may be.
Section 23.  Governing Law . This Agreement shall be governed by, and construed and enforced in accordance with, the laws of the State of Maryland, without regard to its conflicts of laws rules.
[SIGNATURE PAGE FOLLOWS]
    


12



IN WITNESS WHEREOF, the parties hereto have executed this Agreement on the day and year first above written.

HEALTHCARE TRUST OF AMERICA, INC.

By:
 
 
Name:
 
Title:


INDEMNITEE


 
 
 
Name:
 
Title:

    


[SIGNATURE PAGE TO THE INDEMNIFICATION AGREEMENT]
 

EXHIBIT A

AFFIRMATION AND UNDERTAKING TO REPAY EXPENSES ADVANCED
To: The Board of Directors of Healthcare Trust of America, Inc.
Re: Affirmation and Undertaking
Ladies and Gentlemen:
This Affirmation and Undertaking is being provided pursuant to that certain Indemnification Agreement, dated the          day of _________, 20___, by and between Healthcare Trust of America, Inc., a Maryland corporation (the “Company”), and the undersigned Indemnitee (the “Indemnification Agreement”), pursuant to which I am entitled to advance of Expenses in connection with [Description of Proceeding] (the “Proceeding”).
Terms used herein and not otherwise defined shall have the meanings specified in the Indemnification Agreement.
I am subject to the Proceeding by reason of my Corporate Status or by reason of alleged actions or omissions by me in such capacity. I hereby affirm my good faith belief that at all times, insofar as I was involved as a director or officer of the Company, in any of the facts or events giving rise to the Proceeding, I (1) did not act with bad faith or active or deliberate dishonesty, (2) did not receive any improper personal benefit in money, property or services and (3) in the case of any criminal proceeding, had no reasonable cause to believe that any act or omission by me was unlawful.
In consideration of the advance of Expenses by the Company for reasonable attorneys’ fees and related Expenses incurred by me in connection with the Proceeding (the “Advanced Expenses”), I hereby agree that if, in connection with the Proceeding, it is established that (1) an act or omission by me was material to the matter giving rise to the Proceeding and (a) was committed in bad faith or (b) was the result of active and deliberate dishonesty or (2) I actually received an improper personal benefit in money, property or services or (3) in the case of any criminal proceeding, I had reasonable cause to believe that the act or omission was unlawful, then I shall promptly reimburse the portion of the Advanced Expenses relating to the claims, issues or matters in the Proceeding as to which the foregoing findings have been established.

A-1

 

IN WITNESS WHEREOF, I have executed this Affirmation and Undertaking on this          day of __________, 20        .


_______________________________
Name:    



A-2

 


Exhibit 31.1
CERTIFICATION
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Scott D. Peters, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
By:
/s/ Scott D. Peters  
 
 
 
Scott D. Peters 
 
 
 
Chief Executive Officer, President and Chairman
 

Date: July 29, 2015





Exhibit 31.2
CERTIFICATION
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Robert A. Milligan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc.;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
By:
/s/ Robert A. Milligan
 
 
 
Robert A. Milligan
 
 
 
Chief Financial Officer
 

Date: July 29, 2015





Exhibit 31.3
CERTIFICATION
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Scott D. Peters, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
By:
/s/ Scott D. Peters  
 
 
 
Scott D. Peters 
 
 
 
Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

 

Date: July 29, 2015





Exhibit 31.4
CERTIFICATION
Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
I, Robert A. Milligan, certify that:
1. I have reviewed this Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 
By:
/s/ Robert A. Milligan
 
 
 
Robert A. Milligan
 
 
 
Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP

 

Date: July 29, 2015





Exhibit 32.1
CERTIFICATION
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the period ended June 30, 2015 , as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
By:
/s/ Scott D. Peters  
 
 
 
Scott D. Peters
 
 
 
Chief Executive Officer, President and Chairman
 
Date: July 29, 2015






Exhibit 32.2
CERTIFICATION
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America, Inc., or the Company, for the period ended June 30, 2015 , as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
By:
/s/ Robert A. Milligan
 
 
 
Robert A. Milligan
 
 
 
Chief Financial Officer
 
Date: July 29, 2015






Exhibit 32.3
CERTIFICATION
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the period ended June 30, 2015 , as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Scott D. Peters, Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
By:
/s/ Scott D. Peters  
 
 
 
Scott D. Peters
 
 
 
Chief Executive Officer, President and Chairman of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP
 
Date: July 29, 2015





Exhibit 32.4
CERTIFICATION
Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
In connection with the Quarterly Report on Form 10-Q of Healthcare Trust of America Holdings, LP, or the Company, for the period ended June 30, 2015 , as filed with the Securities and Exchange Commission on the date hereof, or the Report, I, Robert A. Milligan, Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(i) the Report fully complies with the requirements of Section 13(a) or Section 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and
(ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

 
By:
/s/ Robert A. Milligan
 
 
 
Robert A. Milligan
 
 
 
Chief Financial Officer of Healthcare Trust of America, Inc., general partner of Healthcare Trust of America Holdings, LP
 
Date: July 29, 2015